Bull Pharmachem
Bull Pharmachem
Kalbadevi, Mumbai, Maharashtra
GST No. 27AKFPJ6383E1Z2
TrustSEAL Verified
Call 08048419840 88% Response Rate
SEND EMAIL

Anti Cancer Drugs

Prominent & Leading Exporter from Mumbai, we offer lenvakast (lenvatinib 4mg ,10mg), lenvima (lenvatinib 4mg ,10mg), bdfoie (lenvatinib 4mg ,10mg), lenvatinib 4mg ,10mg, rydapt (midostaurin 25mg) and midostaurin 25mg.

Lenvakast (Lenvatinib 4MG ,10MG)

Lenvakast (Lenvatinib 4MG ,10MG)
  • Lenvakast (Lenvatinib 4MG ,10MG)
  • Lenvakast (Lenvatinib 4MG ,10MG)
  • Lenvakast (Lenvatinib 4MG ,10MG)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size30 Capsule
Strength4mg ,10mg
BrandLenvakast
CompositionLenvatinib
ManufacturerAprazer Heathcare
TreatmentThyroid Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years
Storage25 DegreeC (77 DegreeF)
Medicine TypeAllopathic
Packaging TypeStrips

Lenvakast (Lenvatinib 4mg ,10mg) is a prescription medicine that is used to treat certain kinds of cancer.
Lenvakast is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingLenvakast is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineLenvakast is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if Lenvakast is safe and effective in children.
IMPORTANT SAFETY INFORMATIONLenvakast may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of Lenvakast and can be serious. Your blood pressure should be well controlled before you start taking Lenvakast. Your healthcare provider should check your blood pressure regularly during treatment with Lenvakast. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: Lenvakast can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: Lenvakast may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with Lenvakast. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with Lenvakast treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of Lenvakast and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with Lenvakast
diarrhea: Diarrhea is a common side effect of Lenvakast and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with Lenvakast to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with Lenvakast and may tell you to take a calcium supplement if your calcium levels are low.

Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Lenvima (Lenvatinib 4MG ,10MG)

Lenvima (Lenvatinib 4MG ,10MG)
  • Lenvima (Lenvatinib 4MG ,10MG)
  • Lenvima (Lenvatinib 4MG ,10MG)
  • Lenvima (Lenvatinib 4MG ,10MG)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size20 Capsule
Strength4mg ,10mg
BrandLenvima
CompositionLenvatinib
ManufacturerEisai Co. Ltd
TreatmentThyroid Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years
Storage25 DegreeC (77 DegreeF)
Medicine TypeAllopathic

LENVIMA (lenvatinib 4mg 10mg) is a prescription medicine that is used to treat certain kinds of cancer.
LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingLENVIMA is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineLENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if LENVIMA is safe and effective in children.
IMPORTANT SAFETY INFORMATIONLENVIMA may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your healthcare provider should check your blood pressure regularly during treatment with LENVIMA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: LENVIMA can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: LENVIMA may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with LENVIMA. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with LENVIMA
diarrhea: Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with LENVIMA to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with LENVIMA and may tell you to take a calcium supplement if your calcium levels are low.


Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Bdfoie (Lenvatinib 4MG ,10MG)

Bdfoie (Lenvatinib 4MG ,10MG)
  • Bdfoie (Lenvatinib 4MG ,10MG)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size30 Capsule
BrandBDFOIE
ManufacturerBDR Pharma
Composition4mg ,10mg
TreatmentThyroid Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
Shelf Life2 Years
FormCapsule

BDFOIE (Lenvatinib 4mg ,10mg) is a prescription medicine that is used to treat certain kinds of cancer.
BDFOIE is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingBDFOIE is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineBDFOIE is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if BDFOIE is safe and effective in children.
IMPORTANT SAFETY INFORMATIONBDFOIE may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of BDFOIE and can be serious. Your blood pressure should be well controlled before you start taking BDFOIE. Your healthcare provider should check your blood pressure regularly during treatment with BDFOIE. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: BDFOIE can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: BDFOIE may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with BDFOIE. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with BDFOIE treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of BDFOIE and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with BDFOIE
diarrhea: Diarrhea is a common side effect of BDFOIE and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with BDFOIE to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with BDFOIE and may tell you to take a calcium supplement if your calcium levels are low.



Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Lenvatinib 4MG ,10MG

Lenvatinib 4MG ,10MG
  • Lenvatinib 4MG ,10MG
  • Lenvatinib 4MG ,10MG
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size20 Capsule
Strength4mg ,10mg
CompositionLenvatinib
TreatmentThyroid Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

Lenvatinib 4mg ,10mg  is a prescription medicine that is used to treat certain kinds of cancer.
Lenvatinib  is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingLenvatinib  is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineLenvatinib  is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if Lenvatinib  is safe and effective in children.
IMPORTANT SAFETY INFORMATIONLenvatinib  may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of Lenvatinib  and can be serious. Your blood pressure should be well controlled before you start taking Lenvatinib  . Your healthcare provider should check your blood pressure regularly during treatment with Lenvatinib  . If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: Lenvatinib  can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: Lenvatinib  may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with Lenvatinib  . Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with Lenvatinib  treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of Lenvatinib  and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with Lenvatinib  
diarrhea: Diarrhea is a common side effect of Lenvatinib  and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with Lenvatinib  to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG.

Request
Callback


Additional Information:

  • Delivery Time: immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Rydapt (Midostaurin 25mg)

Rydapt (Midostaurin 25mg)
  • Rydapt (Midostaurin 25mg)
  • Rydapt (Midostaurin 25mg)
  • Rydapt (Midostaurin 25mg)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size56 Capsule
Strength25mg
BrandRydapt
CompositionMidostaurin
ManufacturerNovartis Pharmaceuticals
TreatmentAcute myeloid leukemia
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years
Storage25 DegreeC (77 DegreeF)
Country of OriginMade in India

Rydapt (Midostaurin 25mg) is a brand-name prescription medication. It’s approved to treat the following conditions in adults: Newly diagnosed acute myeloid leukemia (AML) in people with a certain genetic mutation. AML is a type of cancer that’s found in your blood and bone marrow. Rydapt is given to people with AML who have an abnormal (mutated) FLT3 gene. For this use, Rydapt is used in combination with chemotherapy drugs. Certain types of systemic mastocytosis. This condition affects certain blood cells called mast cells. In some cases, it can lead to blood cancer. Rydapt can be used alone to treat the following types of systemic mastocytosis: aggressive systemic mastocytosis (ASM) systemic mastocytosis that occurs with a form of cancer called associated hematological neoplasm (SM-AHN) mast cell leukemia (MCL), which is a type of cancer that may develop from ASM Rydapt comes as capsules that are taken by mouth twice daily. It contains the drug midostaurin, which belongs to a class of drugs called kinase inhibitors. (A class of drugs describes medications that work in the same way.) Rydapt isn’t considered a chemotherapy drug. Chemotherapy refers to traditional drugs used to treat cancer. These drugs typically affect both cancer cells and normal cells in your body. Rydapt, on the other hand, is a targeted drug. It’s designed to work mainly on cancer cells. FDA approval In 2017, the Food and Drug Administration (FDA) approved Rydapt for use. It was the first targeted therapy drug approved to treat AML. Effectiveness In a clinical study, Rydapt was effective in treating AML. People in this study were given either Rydapt or a placebo (treatment with no active drug). Both groups of people were also given chemotherapy drugs. The results showed the following: People taking Rydapt were 23% more likely to still be alive after at least 3.5 years than were people taking the placebo. About 50% of the people taking Rydapt went at least 8 months without having certain complications caused by their cancer. In comparison, about 50% of people taking the placebo went at least 3 months without having certain complications caused by their cancer. In another clinical study, Rydapt was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Rydapt alone had complete remission* or partial remission.** These results were reported after six cycles of treatment. (The length of these treatment cycles varied.) * With complete remission, the people had an absence of mutated (abnormal) mast cells. ** With partial remission, the people had reduced activity of mutated mast cells. Rydapt generic Rydapt is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication. Rydapt contains the active ingredient midostaurin. Rydapt cost As with all medications, the cost of Rydapt can vary. The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use. Your insurance plan may require you to get prior authorization before approving coverage for Rydapt. This means that your doctor and insurance company will need to communicate about your prescription before the insurance company will cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Rydapt. If you’re not sure if you’ll need to get prior authorization for Rydapt, contact your insurance company. .
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Midostaurin 25mg

Midostaurin 25mg
  • Midostaurin 25mg
  • Midostaurin 25mg
  • Midostaurin 25mg
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size56 Capsule
Strength25mg
CompositionMidostaurin
TreatmentAcute myeloid leukemia
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

Midostaurin 25mg  is a brand-name prescription medication. It’s approved to treat the following conditions in adults:  Newly diagnosed acute myeloid leukemia (AML) in people with a certain genetic mutation. AML is a type of cancer that’s found in your blood and bone marrow. Midostaurin is given to people with AML who have an abnormal (mutated) FLT3 gene. For this use, Midostaurin is used in combination with chemotherapy drugs. Certain types of systemic mastocytosis. This condition affects certain blood cells called mast cells. In some cases, it can lead to blood cancer. Midostaurin can be used alone to treat the following types of systemic mastocytosis: aggressive systemic mastocytosis (ASM) systemic mastocytosis that occurs with a form of cancer called associated hematological neoplasm (SM-AHN) mast cell leukemia (MCL), which is a type of cancer that may develop from ASM Midostaurin comes as capsules that are taken by mouth twice daily. It contains the drug midostaurin, which belongs to a class of drugs called kinase inhibitors. (A class of drugs describes medications that work in the same way.)  Midostaurin isn’t considered a chemotherapy drug. Chemotherapy refers to traditional drugs used to treat cancer. These drugs typically affect both cancer cells and normal cells in your body. Midostaurin , on the other hand, is a targeted drug. It’s designed to work mainly on cancer cells.  FDA approval In 2017, the Food and Drug Administration (FDA) approved Midostaurin for use. It was the first targeted therapy drug approved to treat AML.  Effectiveness In a clinical study, Midostaurin was effective in treating AML. People in this study were given either Midostaurin or a placebo (treatment with no active drug). Both groups of people were also given chemotherapy drugs. The results showed the following:  People taking Midostaurin were 23% more likely to still be alive after at least 3.5 years than were people taking the placebo. About 50% of the people taking Midostaurin went at least 8 months without having certain complications caused by their cancer. In comparison, about 50% of people taking the placebo went at least 3 months without having certain complications caused by their cancer. In another clinical study, Midostaurin was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Midostaurin alone had complete remission* or partial remission.** These results were reported after six cycles of treatment. (The length of these treatment cycles varied.)  * With complete remission, the people had an absence of mutated (abnormal) mast cells.  ** With partial remission, the people had reduced activity of mutated mast cells.  Midostaurin generic Midostaurin is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication.  Midostaurin contains the active ingredient midostaurin.  Midostaurin cost As with all medications, the cost of Midostaurin can vary.  The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use.  Your insurance plan may require you to get prior authorization before approving coverage for Midostaurin . This means that your doctor and insurance company will need to communicate about your prescription before the insurance company will cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Midostaurin .  If you’re not sure if you’ll need to get prior authorization for Midostaurin , contact your insurance company. 
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Nitib ( Ibrutinib 140 MG)

Nitib ( Ibrutinib 140 MG)
  • Nitib ( Ibrutinib 140 MG)
  • Nitib ( Ibrutinib 140 MG)
Get Best Quote
Approx. Price: Rs 10 / CapsuleGet Latest Price

Product Details:

Packaging Size30 Capsule
Strength140 mg
BrandNitib
CompositionIbrutinib
ManufacturerHetero Healthcare Limited
TreatmentBlood cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 years
Storage20 DegreeC to 25 DegreeC
Country of OriginMade in India

Nitib (Ibrutinib 40mg)contains the Drug/Molecule called “Ibrutinib”. Nitib is a small molecule drug that is used to bind permanently to a protein called “Bruton’s tyrosine kinase (BTK)” which is important in B cells.

Nitib 140 mg Uses –
Ibrunat is kind of a medicine which is prescribed for treating adult patients who has the following types of blood cancers:

Mantle cell lymphoma
Waldenstrom’s macroglobulinemia
Chronic Graft Versus Host Disease
Chronic lymphocytic leukemia and
Marginal zone lymphoma (MZL)
Small Lymphocytic Lymphoma
Nitib Ibrutinib is a first line treatment in the people who are newly diagnosed with CLL (Chronic lymphocytic leukemia) blood cancer & require treatment. These capsules may also be used in CLL (Chronic lymphocytic leukemia) that relapses.

How Nitib Ibrutinib 140 mg Capsule Works
Ibrutinib which is the active ingredient in Nitib 140 mg capsules, works in a manner that it blocks the activity of a specific protein called “Bruton’s tyrosine kinase”, or BTK.

Bruton’s tyrosine kinase is a protein that is found in your B cells and it sends “signals” to the other parts of the body that help B cells to survive and multiply.

But these generic ibrunat capsules block BTK & help in killing and reducing the number of cancerous B-cells. Therefore, this stops or slows the progression of cancer.

How to Take Nitib Capsule
It is prescribed to take Nitib 140 mg once in a day at about the same time every day. The dosage and duration of treatment depends on the type of blood cancer, the age of the patient, and on how severe the condition of the patient.

Moreover, it also depends on “how the patient’s body reacts to the first dose.” The Hetero Nitib Capsules should be taken orally with a glass of water. Please remember to not to open, crush, or chew the capsules.

Side Effects of Nitib Capsules –
Nitib can cause side effects like:

Bleeding,
Leukostasis,
Infections,
Decrease the blood cell counts,
Heart problems, or
Liver problems.
There are chances of occurring the new cancers in people taking Ibrunat, including skin cancer & other cancers.

The most common side effects may include:

Pneumonia,
Upper respiratory tract infection,
Diarrhea,
Feeling very tired,
nausea,
headache,
swollen hands,
ankles or feet,
being short of breath,
dizziness,
fainting,
constipation, and
infected nose.
Interactions with other drugs –

Some antiplatelet drugs like “Clopidogrel”, “NSAIDs like Ibuprofen / Naproxen”, “Blood thinners like Warfarin / Dabigatran” can cause bleeding / bruising with Nitib capsules.
The drug called aspirin can increase the risk of bleeding if it is used with Nitib Ibrutinib.
And lastly, the azole antifungals drugs such as “Itraconazole”, “Ketoconazole” can affect the removal of Nitib from body.

Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Vitrakvi (Larotrectinib 25mg)

Vitrakvi  (Larotrectinib 25mg)
  • Vitrakvi  (Larotrectinib 25mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Piece
Packaging Size60 Capsule
Strength25mg
BrandVitrakvi
CompositionLarotrectinib
ManufacturerBayer Heathcare
TreatmentTumors
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years
Side EffectNA
Storage20 DegreeC to 25 DegreeC (68 DegreeF to 77 DegreeF)
Country of OriginMade in India

VITRAKVI (Larotrectinib 25mg )is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that: are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatment. Your healthcare provider will perform a test to make sure that VITRAKVI is right for you. It is not known if VITRAKVI is safe and effective in children younger than 1 month of age. What are the possible side effects of VITRAKVI? VITRAKVI may cause serious side effects, including: Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop symptoms of a nervous system problem with VITRAKVI. Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with VITRAKVI. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop liver problems with VITRAKVI. The most common side effects of VITRAKVI include: tiredness nausea dizziness vomiting cough constipation diarrhea VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects with VITRAKVI. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTION Larotrectinib is a kinase inhibitor. VITRAKVI (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure: VITRAKVI® (larotrectinib) Structural Formula - Illustration Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility). VITRAKVI (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink. The oral solution contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Larotrectinib 25 MG

Larotrectinib 25 MG
  • Larotrectinib 25 MG
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size60 Capsule
Strength25mg ,100mg
CompositionLarotrectinib
TreatmentTumors
Prescription/Non prescriptionPrescription
FormCapsule
Shelf life2 Years
Storage20 DegreeC to 25 DegreeC (68 DegreeF to 77 DegreeF)
Country of OriginMade in India

Larotrectinib 25mgis a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:  are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatment. Your healthcare provider will perform a test to make sure that Larotrectinib is right for you.  It is not known if Larotrectinib is safe and effective in children younger than 1 month of age.  What are the possible side effects of Larotrectinib?  Larotrectinib may cause serious side effects, including:  Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop symptoms of a nervous system problem with Larotrectinib. Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with Larotrectinib. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop liver problems with Larotrectinib. The most common side effects of Larotrectinib include:  tiredness nausea dizziness vomiting cough constipation diarrhea Larotrectinib may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.  These are not all the possible side effects with Larotrectinib. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  DESCRIPTION Larotrectinib is a kinase inhibitor. Larotrectinib (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure:  Larotrectinib® (larotrectinib) Structural Formula - Illustration Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility).  Larotrectinib (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink.  The oral solution contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.


Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

NINLARO (Ixazomib 3mg,4mg)

NINLARO (Ixazomib 3mg,4mg)
  • NINLARO (Ixazomib 3mg,4mg)
  • NINLARO (Ixazomib 3mg,4mg)
  • NINLARO (Ixazomib 3mg,4mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Packaging Size3 Capsule
Strength3mg,4mg
BrandNINLARO
CompositionIxazomib
ManufacturerTakeda Pharmaceutical Company Limited
TreatmentBlood Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

NINLARO (Ixazomib 3mg,4mg) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID (lenalidomide) and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma. It is not known if NINLARO is safe and effective in children. What are the possible side effects of NINLARO? NINLARO may cause serious side effects, including: Low platelet counts (thrombocytopenia). Low platelet counts are common with NINLARO, and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising. Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO, and can sometimes be severe. Call your healthcare provider if you get any of these symptoms and they do not go away during treatment with NINLARO. Your healthcare provider may prescribe medicine to help treat your symptoms. Nerve problems. Nerve problems are common with NINLARO and may also be severe. Tell your healthcare provider if you get any new or worsening symptoms, including: tingling numbness pain a burning feeling in your feet or hands weakness in your arms or legs Swelling. Swelling is common with NINLARO and can sometimes be severe. Tell your healthcare provider if you develop swelling in your arms, hands, legs, ankles, or feet, or if you gain weight from swelling. Skin reactions. Tell your healthcare provider if you get a new or worsening rash. Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs, and may lead to death. Get medical help right away if you get any of the following signs or symptoms during treatment with NINLARO: fever bruising nose bleeds tiredness decreased urination Liver problems. Tell your healthcare provider if you get these signs of a liver problem: yellowing of your skin or the whites of your eyes pain in your right upper stomach-area Other common side effects have occurred. Tell your healthcare provider if you get new or worsening signs or symptoms of the following: back pain skin rash and pain (shingles) as a result of reactivation of the chicken pox virus (herpes zoster) lowered white blood cells called neutrophils (neutropenia) that may increase the risk of infection vision conditions including blurred vision, dry eye and pink eye (conjunctivitis) These are not all the possible side effects of NINLARO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTION NINLARO (ixazomib) is an antineoplastic agent. Ixazomib citrate, a prodrug, rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib. The chemical name of ixazomib citrate is 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-and the structural formula is: NINLARO® (ixazomib) Structural Formula Illustration The molecular formula for ixazomib citrate is C20H23BCl2N2O9 and its molecular weight is 517.12. Ixazomib citrate has one chiral center and is the R-stereoisomer. The solubility of ixazomib citrate in 0.1N HCl (pH 1.2) at 37°C is 0.61 mg/mL (reported as ixazomib). The solubility increases as the pH increases. NINLARO (ixazomib) capsules for oral use contain 4, 3 or 2.3 mg of ixazomib equivalent to 5.7, 4.3 or 3.3 mg of ixazomib citrate, respectively. Inactive ingredients include microcrystalline cellulose, magnesium stearate, and talc. Capsule shells contain gelatin and titanium dioxide. The 4 mg capsule shell contains red and yellow iron oxide, the 3 mg capsule shell contains black iron oxide and the 2.3 mg capsule shell contains red iron oxide.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Piqray (Alpelisib 300mg)

Piqray (Alpelisib 300mg)
  • Piqray (Alpelisib 300mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Packaging Size28 Tablets
Strength300mg
BrandPIQRAY
CompositionAlpelisib
ManufacturerNovartis
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormTablet

PIQRAY (Alpelisib 300mg) tablets is contraindicated in patients with severe hypersensitivity to it or any of its components Indication PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Important Safety Information PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components. Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia. The incidence of grade 3 and 4 hypersensitivity reactions was 0.7%. Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue PIQRAY in the event of severe hypersensitivity. Severe Cutaneous Adverse Reactions (SCARs): SCARs including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY. In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of patients, respectively. DRESS was reported in patients in the postmarketing setting. If signs or symptoms of SCARs occur, interrupt PIQRAY until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous SCARs during PIQRAY treatment. If it is not confirmed, PIQRAY may require dose modifications, topical corticosteroids, or oral antihistamine treatment. Advise patients of the signs and symptoms of SCARs (eg, a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy). Hyperglycemia: Severe hyperglycemia, including ketoacidosis, can occur in patients treated with PIQRAY. Hyperglycemia was reported in 65% of patients treated with PIQRAY. Grade 3 (FPG >250-500 mg/dL) and grade 4 (FPG >500 mg/dL) hyperglycemia were reported in 33% and 3.9% of patients, respectively. Ketoacidosis was reported in 0.7% of patients (n=2) treated with PIQRAY. Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated. If a patient experiences hyperglycemia after initiating treatment with PIQRAY, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated. Consider consultation with a health care practitioner with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes. The safety of PIQRAY in patients with type 1 and uncontrolled type 2 diabetes has not been established as these patients were excluded from the SOLAR-1 trial. Patients with a medical history of type 2 diabetes were included. Patients with a history of diabetes mellitus may require intensified diabetic treatment. Closely monitor patients with diabetes.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Alpelisib 300mg

Alpelisib 300mg
  • Alpelisib 300mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Packaging Size28 Tablets
Strength300mg
CompositionAlpelisib
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormTablet

Alpelisib 300mg tablets is contraindicated in patients with severe hypersensitivity to it or any of its componentsIndication
PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Important Safety Information
Alpelisib is contraindicated in patients with severe hypersensitivity to it or any of its components.
Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia. The incidence of grade 3 and 4 hypersensitivity reactions was 0.7%. Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue Alpelisib in the event of severe hypersensitivity.
Severe Cutaneous Adverse Reactions (SCARs): SCARs including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY. In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of patients, respectively. DRESS was reported in patients in the postmarketing setting. If signs or symptoms of SCARs occur, interrupt Alpelisib until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.
If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce Alpelisib in patients who have experienced previous SCARs during Alpelisib treatment. If it is not confirmed, Alpelisib may require dose modifications, topical corticosteroids, or oral antihistamine treatment.
Advise patients of the signs and symptoms of SCARs (eg, a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy).
Hyperglycemia: Severe hyperglycemia, including ketoacidosis, can occur in patients treated with PIQRAY. Hyperglycemia was reported in 65% of patients treated with PIQRAY. Grade 3 (FPG >250-500 mg/dL) and grade 4 (FPG >500 mg/dL) hyperglycemia were reported in 33% and 3.9% of patients, respectively. Ketoacidosis was reported in 0.7% of patients (n=2) treated with PIQRAY.
Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated. If a patient experiences hyperglycemia after initiating treatment with PIQRAY, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated. Consider consultation with a health care practitioner with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes.
The safety of Alpelisib in patients with type 1 and uncontrolled type 2 diabetes has not been established as these patients were excluded from the SOLAR-1 trial. Patients with a medical history of type 2 diabetes were included. Patients with a history of diabetes mellitus may require intensified diabetic treatment. Closely monitor patients with diabetes.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Kryxana (Ribociclib 200mg)

Kryxana (Ribociclib 200mg)
  • Kryxana (Ribociclib 200mg)
  • Kryxana (Ribociclib 200mg)
  • Kryxana (Ribociclib 200mg)
  • Kryxana (Ribociclib 200mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size21 Tablets
Strength200 mg
BrandKryxana
CompositionRibociclib
ManufacturerNovartis India Ltd
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

Kryxana (Ribociclib 200mg)  Tablet is an anti-cancer medicine used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them. This way it treats the symptoms of breast cancer such as breast lumps, bloody discharge from nipples, or changes in the shape of the breast.

Kryxana 200mg Tablet may be taken with or without food and usually taken in combination with another medicine. The duration of treatment varies on the basis of your need and response to treatment. Take it in the exact dose and duration prescribed by your doctor. You may be asked for regular blood tests while taking this medication.

Common side effects of this medicine include decreased white blood cell count, nausea, fatigue, diarrhea, hair loss, vomiting, constipation, headache, and back pain. Neutropenia is a well-recognized adverse effect, in which the number of your white blood cells get reduced and your immune system gets weakened. As a result, you may be at greater risk of getting an infection. However, this side effect disappears rapidly once you stop taking the medicine.

Before using this medicine, let your doctor know if you have any preexisting medical conditions. Let your doctor also know about all the medications you are taking. Additionally, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.USES OF KRYXANA TABLET
  • Metastatic breast cancer
BENEFITS OF KRYXANA TABLETIn Metastatic breast cancerKryxana 200mg Tablet helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. This medicine is used when other medicines have not shown significant improvement and the cancer has spread to other parts as well. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Kryxana 200mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.SIDE EFFECTS OF KRYXANA TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of Kryxana
  • Decreased white blood cell count
  • Nausea
  • Fatigue
  • Diarrhea
  • Hair loss
  • Vomiting
  • Constipation
  • Headache
  • Back pain
HOW TO USE KRYXANA TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Kryxana 200mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW KRYXANA TABLET WORKSKryxana 200mg Tablet is an anti-cancer medication. It works by blocking proteins (kinases) which are important for the growth and division of cells. This slows the growth of cancer cells and eventually kills them.SAFETY ADVICEAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Kryxana 200mg Tablet. Please consult your doctor.PregnancyCONSULT YOUR DOCTORKryxana 200mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.BreastfeedingCONSULT YOUR DOCTORKryxana 200mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Ribociclib 200mg

Ribociclib 200mg
  • Ribociclib 200mg
  • Ribociclib 200mg
  • Ribociclib 200mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size21 Tablets
Strength200mg
CompositionRibociclib
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years

Ribociclib 200mg Tablet is an anti-cancer medicine used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them. This way it treats the symptoms of breast cancer such as breast lumps, bloody discharge from nipples, or changes in the shape of the breast.
Ribociclib 200mg Tablet may be taken with or without food and usually taken in combination with another medicine. The duration of treatment varies on the basis of your need and response to treatment. Take it in the exact dose and duration prescribed by your doctor. You may be asked for regular blood tests while taking this medication.
Common side effects of this medicine include decreased white blood cell count, nausea, fatigue, diarrhea, hair loss, vomiting, constipation, headache, and back pain. Neutropenia is a well-recognized adverse effect, in which the number of your white blood cells get reduced and your immune system gets weakened. As a result, you may be at greater risk of getting an infection. However, this side effect disappears rapidly once you stop taking the medicine.
Before using this medicine, let your doctor know if you have any preexisting medical conditions. Let your doctor also know about all the medications you are taking. Additionally, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.USES OF KRYXANA TABLETMetastatic breast cancerBENEFITS OF KRYXANA TABLETIn Metastatic breast cancerRibociclib 200mg Tablet helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. This medicine is used when other medicines have not shown significant improvement and the cancer has spread to other parts as well. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Ribociclib 200mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.SIDE EFFECTS OF KRYXANA TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of Ribociclib Decreased white blood cell countNauseaFatigueDiarrheaHair lossVomitingConstipationHeadacheBack painHOW TO USE KRYXANA TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ribociclib 200mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW KRYXANA TABLET WORKSRibociclib 200mg Tablet is an anti-cancer medication. It works by blocking proteins (kinases) which are important for the growth and division of cells. This slows the growth of cancer cells and eventually kills them.SAFETY ADVICEwarningsAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Ribociclib 200mg Tablet. Please consult your doctor.warningsPregnancyCONSULT YOUR DOCTORRibociclib 200mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTORRibociclib 200mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingUNSAFERibociclib 200mg Tablet may cause side effects which could affect your ability to drive.Some people may experience fatigue, dizziness, or vertigo during treatment with Ribociclib 200mg Tablet. If these happen you should be cautious when driving or using machines.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Polivy (Polatuzumab Vedotin - Piiq 140mg)

Polivy (Polatuzumab Vedotin - Piiq 140mg)
  • Polivy (Polatuzumab Vedotin - Piiq 140mg)
  • Polivy (Polatuzumab Vedotin - Piiq 140mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBottle
Quantity Per Pack1 vial
Packaging Size1vial
BrandPolivy
Country of OriginMade in India
ManufacturerGenentech
Storage2 DegreeC to 8 DegreeC (36 DegreeF to 46 DegreeF)
TreatmentLymphoma
Strength140mg
Sub CategoryAnti Cancer
DISCLAIMERTrademark shown are property of their respective owners and we do not lay any claim on them. Parall

POLIVY (Polatuzumab Vedotin - Piiq 140mg) is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least 2 prior therapies. The conditional approval of POLIVY is based on a type of response rate. There are ongoing studies to establish how well the drug works. Everyone reacts differently to POLIVY therapy, so it’s important to know what the side effects are. Some people who have been treated with POLIVY have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Nerve problems in your arms and legs: This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern Infusion-related reactions: You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion Infections: If you have a fever of 100.4°F (38°C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you POLIVY, which may prevent some infections, and will monitor your blood counts throughout treatment with POLIVY. Treatment with POLIVY can cause severe low blood cell counts Rare and serious brain infections: Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication Side effects seen most often The most common side effects during treatment were Low blood cell counts (platelets, red blood cells, white blood cells) Nerve problems in arms and legs Tiredness or lack of energy Diarrhea Nausea Fever Decreased appetite Infections POLIVY may not be for everyone. Talk to your doctor if you are Pregnant or think you are pregnant: Data have shown that POLIVY may harm your unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking POLIVY. Women should use effective contraception during treatment and for at least 3 months after their last POLIVY treatment. Men taking POLIVY should use effective contraception during treatment and for at least 5 months after their last POLIVY
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Cobimetinib 20mg

Cobimetinib 20mg
  • Cobimetinib 20mg
  • Cobimetinib 20mg
Ask For Price
Product Price :Get Latest Price

Product Details:

PackagingBottle
Country of OriginMade in India
TreatmentLung Cancer
Strength20mg
Pack Size63 Capsule
Delivery TimeImmediate
DISCLAIMERTrademark shown are property of their respective owners and we do not lay any claim on them. Parall

Cobimetinib 20mg is a prescription medicine that is used with the medicine ZELBORAF, to treat a type of skin cancer called melanoma:
that has spread to other parts of the body or cannot be removed by surgery, andthat has a certain type of abnormal “BRAF” geneYour healthcare provider will perform a test to make sure that Cobimetinib 20mg is right for you.It is not known if Cobimetinib 20mg is safe and effective in children under 18 years of age.Before you take Cobimetinib 20mg and ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you:
have skin problems or history of skin problems, other than melanomahave bleeding problems, any medical conditions and/or on any medications that increase your risk of bleeding have heart problems, including a condition called long QT syndromehave eye problemshave liver or kidney problemshave muscle problemshave had or are planning to receive radiation therapyhave been told that you have low blood levels of potassium, calcium, or magnesiumare pregnant or plan to become pregnant. Cobimetinib 20mg and ZELBORAF can harm your unborn baby.Females who are able to become pregnant should use effective birth control during treatment with Cobimetinib 20mg and ZELBORAF, and for 2 weeks after the final dose of Cobimetinib 20mg or ZELBORAF (whichever is taken later).Talk to your healthcare provider about birth control methods that may be right for you.Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Cobimetinib 20mg and ZELBORAF.are breastfeeding or plan to breastfeed. It is not known if Cobimetinib 20mg or ZELBORAF passes into your breast milk. Do not breastfeed during treatment with Cobimetinib 20mg and ZELBORAF and for 2 weeks after the final dose of Cobimetinib 20mg or ZELBORAF (whichever is taken later). Talk to your healthcare provider about the best way to feed your baby during this time.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the blood levels of Cobimetinib 20mg.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take Cobimetinib 20mg and ZELBORAF in combination?
Take Cobimetinib 20mg and ZELBORAF exactly as your healthcare provider tells you. Do not change your dose or stop taking Cobimetinib 20mg and ZELBORAF unless your healthcare provider tells you to.Take Cobimetinib 20mg one time a day for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle.Take ZELBORAF every 12 hours for every day in the 28-day cycle (no rest period).Do not crush or chew ZELBORAF tablets.Take Cobimetinib 20mg and ZELBORAF with or without food.If you vomit after taking your dose of Cobimetinib 20mg or ZELBORAF, do not take an additional dose. Take your next dose as scheduled.If you miss a dose of Cobimetinib 20mg, take your next dose as scheduled.If you miss a dose of ZELBORAF, take it as soon as you remember. If it is within 4 hours of your next scheduled dose, just take your next dose at your regular time. Do not make up for the missed dose.If you take too much ZELBORAF, call your healthcare provider or go the nearest hospital emergency room right away.What should I avoid during treatment with Cobimetinib 20mg and ZELBORAF?
Avoid sunlight during treatment with Cobimetinib 20mg and ZELBORAF. Cobimetinib 20mg and ZELBORAF can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn:
When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs.Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher.
Request
Callback
Yes! I am Interested

Calquence (Acalabrutinib 100mg)

Calquence (Acalabrutinib 100mg)
  • Calquence (Acalabrutinib 100mg)
  • Calquence (Acalabrutinib 100mg)
  • Calquence (Acalabrutinib 100mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size12 Capsule
BrandCalquence
ManufacturerAstraZeneca Pharmaceuticals
CompositionAcalabrutinib
TreatmentLymphoma
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
Shelf Life2 Years
FormCapsule

Calquence (Acalabrutinib 100mg) is the generic name for the trade name drug Calquence. In some cases, health care professionals may use the trade name Calquence when referring to the generic drug name acalabrutinib. Drug Type: Acalabrutinib is a targeted therapy. Acalabrutinib inhibits the function of Bruton's tyrosine kinase (BTK) (for more detail, see "How Acalabrutinib Works" below). What Acalabrutinib Is Used For The treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. How Acalabrutinib Is Given Acalabrutinib is a 100 mg capsule, taken by mouth twice daily. Take acalabrutinib approximately 12 hours apart at the same time each day. Swallow acalabrutinib capsules whole with at least 8 ounces of water. Do not crush, open, chew or dissolve capsules. Take acalabrutinib with or without food. If you miss a dose by more than 3 hours, omit that dose and take the next dose at the regularly scheduled time; do not take extra doses to make up for a missed dose. The amount of acalabrutinib that you will receive depends on many factors including your general health or other health problems, other medications you may be taking, and severity or tolerance of side effects. Your doctor will determine your exact dosage and schedule. Side Effects Important things to remember about the side effects of acalabrutinib: Most people will not experience all of the acalabrutinib side effects listed. Acalabrutinib side effects are often predictable in terms of their onset, duration, and severity. Acalabrutinib side effects are almost always reversible and should improve after treatment is stopped Acalabrutinib side effects may be quite manageable. There are many options to minimize or prevent the side effects of acalabrutinib. There is no relationship between the presence and/or severity of side effects and the effectiveness of the medication. Always report side effects to your healthcare provider. The following side effects are common (occurring in greater than 30%) for patients taking acalabrutinib: Headache Diarrhea These are less common side effects (occurring in 10-29%) for patients receiving acalabrutinib: Low blood counts. Your white and red blood cells and platelets may temporarily decrease. This can put you at increased risk for infection, anemia and/or bleeding. Fatigue Bruising Muscle pain Nausea Rash Abdominal pain Constipation Vomiting A rare, but potentially serious side effect of acalabrutinib is heart rhythm changes (arrhythmias), including atrial fibrillation and atrial flutter. Not all side effects are listed above. Side effects that are very rare - occurring in less than about 10 percent of patients - are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms. When to Contact Your Health Care Provider Contact your health care provider immediately, day or night, if you should experience any of the following symptoms: Fever of 100.4º F (38º C) or higher, chills Shortness of breath, cough or trouble breathing Any bleeding that won't stop The following symptoms require medical attention, but are not an emergency.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Nerlynx (Neratinib 40mg)

Nerlynx (Neratinib 40mg)
  • Nerlynx (Neratinib 40mg)
  • Nerlynx (Neratinib 40mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Packaging Size180 Tablets
Strength40mg
BrandNERLYNX
CompositionNeratinib
ManufacturerPuma Biotech
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years

NERLYNX (Neratinib 40mg) is a prescription medicine used alone to treat adults with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who have previously been treated with trastuzumab-based therapy. NERLYNX is also used with a medicine called capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) and who have received 2 or more anti-HER2 therapy medicines for metastatic breast cancer. It is not known if NERLYNX is safe and effective in children. Before taking NERLYNX, tell your healthcare provider about all of your medical conditions, including if you: have liver problems. You may need a lower dose of NERLYNX. are pregnant or plan to become pregnant. NERLYNX can harm your unborn baby. If you are a female who can become pregnant: Your healthcare provider should do a pregnancy test before you start taking NERLYNX. You should use effective birth control (contraception) during treatment and for at least 1 month after your last dose of NERLYNX. Talk with your healthcare provider about forms of birth control that you can use during this time. Tell your healthcare provider right away if you become pregnant during treatment with NERLYNX. Males with female partners who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of NERLYNX. are breastfeeding or plan to breastfeed. It is not known if NERLYNX passes into your breast milk. Do not breastfeed during treatment and for at least 1 month after your last dose of NERLYNX. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines used to decrease stomach acid, called proton pump inhibitors or PPIs. You should avoid taking these medicines during treatment with NERLYNX. What are the possible side effects of NERLYNX? NERLYNX may cause serious side effects, including: See "What is the most important information I should know about NERLYNX?" Liver problems. Changes in liver function tests are common with NERLYNX. Your healthcare provider should do blood tests before you begin treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. Your healthcare provider will stop your treatment with NERLYNX if your liver tests show severe problems. Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems: tiredness nausea vomiting pain in the right upper stomach-area (abdomen) fever rash itching yellowing of your skin or whites of your eyes The most common side effects of NERLYNX when used alone include: diarrhea nausea stomach-area (abdomen) pain tiredness vomiting rash dry or inflamed mouth, or mouth sores decreased appetite muscle spasms upset stomach nail problems including color change dry skin swelling of your stomach-area nosebleed weight loss urinary tract infection The most common side effects of NERLYNX in combination with capecitabine include: diarrhea nausea vomiting decreased appetite constipation tiredness/weakness weight loss dizziness back pain joint pain urinary tract infection upper respiratory tract infection swelling of your stomach-area kidney problems muscle spasms
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Neratinib 40mg

Neratinib 40mg
  • Neratinib 40mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Packaging Size180 Tablets
Strength40 mg
CompositionNeratinib
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years

Neratinib 40mg is a prescription medicine used alone to treat adults with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who have previously been treated with trastuzumab-based therapy.Neratinib  is also used with a medicine called capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) and who have received 2 or more anti-HER2 therapy medicines for metastatic breast cancer.It is not known if Neratinib  is safe and effective in children.
Before taking Neratinib , tell your healthcare provider about all of your medical conditions, including if you:
have liver problems. You may need a lower dose of Neratinib .are pregnant or plan to become pregnant. Neratinib  can harm your unborn baby. If you are a female who can become pregnant:Your healthcare provider should do a pregnancy test before you start taking Neratinib .You should use effective birth control (contraception) during treatment and for at least 1 month after your last dose of Neratinib .Talk with your healthcare provider about forms of birth control that you can use during this time.Tell your healthcare provider right away if you become pregnant during treatment with Neratinib .Males with female partners who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of Neratinib .are breastfeeding or plan to breastfeed. It is not known if Neratinib  passes into your breast milk. Do not breastfeed during treatment and for at least 1 month after your last dose of Neratinib .Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines used to decrease stomach acid, called proton pump inhibitors or PPIs. You should avoid taking these medicines during treatment with Neratinib .
What are the possible side effects of Neratinib ?
Neratinib  may cause serious side effects, including:See "What is the most important information I should know about Neratinib ?"

Liver problems. Changes in liver function tests are common with Neratinib . Your healthcare provider should do blood tests before you begin treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with Neratinib . Your healthcare provider will stop your treatment with Neratinib  if your liver tests show severe problems. Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems:tirednessnauseavomitingpain in the right upper stomach-area (abdomen)feverrashitchingyellowing of your skin or whites of your eyesThe most common side effects of Neratinib  when used alone include:
diarrheanauseastomach-area (abdomen) paintirednessvomitingrashdry or inflamed mouth, or mouth soresdecreased appetitemuscle spasmsupset stomachnail problems including color changedry skinswelling of your stomach-areanosebleedweight lossurinary tract infectionThe most common side effects of Neratinib  in combination with capecitabine include:
diarrheanauseavomitingdecreased appetiteconstipationtiredness/weaknessweight lossdizzinessback painjoint painurinary tract infectionupper respiratory tract infectionswelling of your stomach-areakidney problemsmuscle spasms
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Lartruvo (Olaratumab 10mg)

Lartruvo (Olaratumab 10mg)
  • Lartruvo (Olaratumab 10mg)
  • Lartruvo (Olaratumab 10mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Vial
Packaging Size1 Vial
Strength10mg
BrandLartruvo
CompositionOlaratumab
ManufacturerEli Lilly and Company
TreatmentSoft Tissue Sarcoma
Prescription/Non prescriptionPrescription
FormInjection
Deals inThird Party Manufacturing
Shelf life2 Years

LARTRUVO (Olaratumab 10mg)is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. This indication is approved under accelerated approval [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DOSAGE AND ADMINISTRATION Recommended Dosage The recommended dose of LARTRUVO is 15 mg/kg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. For the first 8 cycles, LARTRUVO is administered with doxorubicin, [see Clinical Studies]. Refer to doxorubicin prescribing information for dosing, and dose modifications. Premedication Premedicate with diphenhydramine (25 to 50 mg intravenously) and dexamethasone (10 to 20 mg intravenously) prior to LARTRUVO on Day 1 of cycle 1. Dosing Modifications Infusion-Related Reactions Permanently discontinue LARTRUVO for Grade 3 or 4 infusion-related reactions [see Premedication and WARNINGS AND PRECAUTIONS]. Interrupt infusion of LARTRUVO for Grade 1 or 2 infusion-related reactions (IRR). After resolution, resume LARTRUVO infusion at 50% of the initial infusion rate. [see WARNINGS AND PRECAUTIONS] Neutropenia For neutropenic fever/infection or Grade 4 neutropenia lasting longer than 1 week, discontinue administration of LARTRUVO until the absolute neutrophil count is 1,000 /microliter or greater and then permanently reduce the dose to 12 mg/kg. Preparation And Administration Preparation Inspect vial contents for particulate matter and discoloration prior to dilution [see DESCRIPTION]. Discard the vial if particulate matter or discolorations are identified. Withdraw calculated dose and further dilute with 0.9% Sodium Chloride Injection, USP to a final volume of 250 mL for intravenous infusion. Do not use dextrose-containing or other solutions. Gently invert but do not shake. DO NOT FREEZE the diluted solution. Store the diluted solution for up to 24 hours under refrigeration at 2°C to 8°C (36°F to 46°F) and for up to an additional 4 hours at room temperature (below 25°C [77°F]). Storage times include the duration of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Discard vial with any unused portion of LARTRUVO. Administration Do not administer LARTRUVO as an intravenous push or bolus. Do not co-infuse with electrolytes or other medications through the same intravenous line. Visually inspect the diluted solution for particulate matter and discoloration prior to administration. If particulate matter or discolorations are identified, discard the solution. Administer diluted solution as an intravenous infusion over 60 minutes. Flush the line with 0.9% Sodium Chloride Injection, USP at end of infusion. HOW SUPPLIED Dosage Forms And Strengths Injection: 500 mg/50 mL (10 mg/mL) or 190 mg/19 mL (10 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Zelboraf (Vemurafenib 240mg)

Zelboraf (Vemurafenib 240mg)
  • Zelboraf (Vemurafenib 240mg)
  • Zelboraf (Vemurafenib 240mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Strength240mg
Packaging Size120 Tablet
BrandZELBORAF
CompositionVemurafenib
ManufacturerGenentech
TreatmentSkin Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years

ZELBORAF (Vemurafenib 240mg) is a prescription medicine used to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene. ZELBORAF is not used to treat melanoma with a normal BRAF gene. Your healthcare provider will perform a test to make sure ZELBORAF is right for you. ZELBORAF is a prescription medicine used to treat a type of blood cell cancer called Erdheim–Chester disease (ECD), that can affect body tissues and organs, and that has a certain type of abnormal “BRAF” gene. It is not known if ZELBORAF is safe and effective in children under 18 years of age. Important Safety Information What is the most important information I should know about ZELBORAF? ZELBORAF can cause serious side effects, including: Risk of new cancers. ZELBORAF may cause certain types of skin cancer called cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma. New melanoma lesions have occurred in people who take ZELBORAF. ZELBORAF may also cause another type of cancer called non-cutaneous squamous cell carcinoma (non-cuSCC). Talk with your healthcare provider about your risk for these cancers. Check your skin and tell your healthcare provider right away about any skin changes, including: A new wart A skin sore or reddish bump that bleeds or does not heal A change in size or color of a mole Your healthcare provider should check your skin before you start taking ZELBORAF, and every 2 months during treatment with ZELBORAF, to look for any new skin cancers. Your healthcare provider may continue to check your skin for 6 months after you stop taking ZELBORAF. Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that you get while taking ZELBORAF. Other blood cancers have happened in some people with Erdheim-Chester Disease (ECD) including those who take ZELBORAF. If you have other blood cancers and take ZELBORAF for ECD, your healthcare provider will monitor your blood cancer through routine blood tests. Before you take ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you: Have any heart problems, including a condition called long QT syndrome Have liver or kidney problems Have had or are planning to receive radiation therapy Have been told that you have low blood levels of potassium, calcium, or magnesium Are pregnant or plan to become pregnant. ZELBORAF can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with ZELBORAF and for 2 weeks after the final dose of ZELBORAF Talk to your healthcare provider about birth control methods that may be right for you Tell your healthcare provider right away if you become pregnant during treatment with ZELBORAF Are breastfeeding or plan to breastfeed. It is not known if ZELBORAF passes into your breast milk. Do not breastfeed during treatment with ZELBORAF and for 2 weeks after the final dose of ZELBORAF. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while taking ZELBORAF? Avoid sunlight during treatment with ZELBORAF. ZELBORAF can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn:
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Cuchel ( Trientine Hydrochloride 250mg)

Cuchel ( Trientine Hydrochloride 250mg)
  • Cuchel ( Trientine Hydrochloride 250mg)
  • Cuchel ( Trientine Hydrochloride 250mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size100 Capsule
BrandCUCHEL
ManufacturerMSN LABORATORIES PVT LTD
CompositionTrientine Hydrochloride
TreatmentWilson's Disease
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
Shelf Life2 Years
FormTablet

CUCHEL (Trientine Hydrochloride 250mg) CAPSULE is used to treat a certain inherited disorder (Wilson's disease). This disorder causes too much copper to build up in the liver, brain, and other parts of the body. Trientine works by binding to copper, which helps your body get rid of extra copper. This can decrease symptoms such as problems with speech/swallowing/coordination, tiredness, lack of appetite, abdominal pain, yellowing eyes/skin, fluid buildup in the legs/abdomen, uncontrolled movements, or muscle stiffness. Doctors typically use blood tests and a 24-hour urine collection test to diagnose Wilson disease. Doctors may also use a liver biopsy and imaging tests. For a blood test, a health care professional will take a blood sample from you and send the sample to a lab. There is no cure for Wilson disease. Lifelong treatment is necessary and could include: Taking copper-chelating medications, which help your body's organs and tissues get rid of excess copper. Reducing the amount of copper you get through food.Wilson's disease is a rare inherited disorder that causes copper to accumulate in your liver, brain and other vital organs. Most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well.Filing for Social Security Disability with a Wilson's Disease Diagnosis. Wilson's disease is listed in the Social Security Administration's (SSA) impairment listing manual (more commonly called the “Blue Book”) as one of the conditions which may qualify a person to receive Social Security Disability benefits.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

RUBRACA (Rucaparib 200 MG)

RUBRACA (Rucaparib 200 MG)
  • RUBRACA (Rucaparib 200 MG)
  • RUBRACA (Rucaparib 200 MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size60 Tablets
BrandRUBRACA
CompositionRucaparib
ManufacturerClovis Oncology Inc.
TreatmentOvarian Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

Rubraca (Rucaparib 200 Mg) tablets are a prescription medicine used in adults for: the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you. the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer. Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you. It is not known if Rubraca is safe and effective in children. SELECT IMPORTANT SAFETY INFORMATION What Warnings should I know about Rubraca? Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca. You should not use Rubraca if: You are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca. If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca. Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant. You are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time. If you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca. What other important information should I know about Rubraca? Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Bdparib (Rucaparib 200 Mg)

Bdparib (Rucaparib 200 Mg)
  • Bdparib (Rucaparib 200 Mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Packaging Size60 Tablets
BrandBDPARIB
CompositionRucaparib
ManufacturerBDR Pharma
TreatmentOvarian Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

BDPARIB (Rucaparib 200 Mg) tablets are a prescription medicine used in adults for: the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure BDPARIB is right for you. the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer. BDPARIB was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of BDPARIB. Your healthcare provider will perform a test to make sure BDPARIB is right for you. It is not known if BDPARIB is safe and effective in children. SELECT IMPORTANT SAFETY INFORMATION What Warnings should I know about BDPARIB? BDPARIB tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with BDPARIB, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with BDPARIB. You should not use BDPARIB if: You are pregnant or plan to become pregnant. BDPARIB can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with BDPARIB. If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with BDPARIB. Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of BDPARIB. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant. You are breastfeeding or plan to breastfeed. It is not known if BDPARIB passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of BDPARIB. Talk to your healthcare provider about the best way to feed your baby during this time. If you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of BDPARIB. Do not donate sperm during use and for 3 months after the last dose of BDPARIB. What other important information should I know about BDPARIB? Your healthcare provider will do blood tests before, and every month during treatment with BDPARIB to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with BDPARIB until your blood cell counts improve. Avoid spending time in sunlight while on BDPARIB since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Rucaparib 200 Mg

Rucaparib 200 Mg
  • Rucaparib 200 Mg
  • Rucaparib 200 Mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Packaging Size60 Tablets
CompositionRucaparib
TreatmentOvarian Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

Rucaparib 200 Mg tablets are a prescription medicine used in adults for:the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapythe treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rucaparib 200 Mg is right for you.the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):that has spread to other parts of the body, andhas a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.Rucaparib 200 Mg was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rucaparib 200 Mg. Your healthcare provider will perform a test to make sure Rucaparib 200 Mg is right for you.It is not known if Rucaparib 200 Mg is safe and effective in children.SELECT IMPORTANT SAFETY INFORMATIONWhat Warnings should I know about Rucaparib 200 Mg?Rucaparib 200 Mg tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rucaparib 200 Mg, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rucaparib 200 Mg. You should not use Rucaparib 200 Mg if:You are pregnant or plan to become pregnant. Rucaparib 200 Mg can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rucaparib 200 Mg.If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rucaparib 200 Mg.Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rucaparib 200 Mg.Talk to your healthcare provider about birth control methods that may be right for you.Tell your healthcare provider right away if you become pregnant.You are breastfeeding or plan to breastfeed. It is not known if Rucaparib 200 Mg passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rucaparib 200 Mg. Talk to your healthcare provider about the best way to feed your baby during this time.If you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of Rucaparib 200 Mg. Do not donate sperm during use and for 3 months after the last dose of Rucaparib 200 Mg.What other important information should I know about Rucaparib 200 Mg?Your healthcare provider will do blood tests before, and every month during treatment with Rucaparib 200 Mg to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rucaparib 200 Mg until your blood cell counts improve. Avoid spending time in sunlight while on Rucaparib 200 Mg since your skin may become more sensitive to the sun and may sunburn more easily. 
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Verzenio (Abemaciclib 150 Mg)

Verzenio (Abemaciclib 150 Mg)
  • Verzenio (Abemaciclib 150 Mg)
  • Verzenio (Abemaciclib 150 Mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Packaging Size14 Tablets
BrandVERZENIO
CompositionAbemaciclib
ManufacturerEli Lilly and Company
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

Verzenio (Abemaciclib 150 Mg) is a prescription medicine used to treat a type of breast cancer. It is a medicine you can take if: You have a type of breast cancer called HR+/HER2– (hormone receptor positive/human epidermal growth factor receptor 2–negative) and the cancer has spread to other parts of the body (metastasized) Verzenio is given along with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, along with fulvestrant in women whose disease has progressed after hormonal therapy, or by itself in adults whose disease has progressed after hormone therapy and prior chemotherapy It is not known if Verzenio is safe and effective in children. Warnings Verzenio may cause serious side effects, including: Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea. At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids. Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills. Verzenio may cause severe or life-threatening inflammation (swelling) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain Verzenio can cause liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems: Feeling very tired Loss of appetite Pain on the upper right side of your stomach area (abdomen) Bleeding or bruising more easily than normal Verzenio may cause blood clots in your veins or lungs. These may be serious and have led to death. Tell your doctor if you have the following signs and symptoms of a blood clot: Pain or swelling in your arms or legs Fast breathing Shortness of breath Fast heart rate Chest pain Verzenio can harm your unborn baby. Use effective birth control during treatment and for at least 3 weeks after the last dose of Verzenio and do not breastfeed during treatment with Verzenio and for at least 3 weeks after your last dose. Verzenio may affect the ability of males to father a child. Common side effects The most common side effects of Verzenio include: Nausea Abdominal pain Infections Tiredness Low red blood cell counts (anemia) Low white blood cell counts (leukopenia) Decreased appetite Vomiting Headache Low platelet counts (thrombocytopenia) Hair thinning or hair loss (alopecia) These are not all the possible side effects of Verzenio. Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. Before using Before you use Verzenio, tell your doctor: If you have fever, chills, or other signs of infection Have liver or kidney problems About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take a medicine that contains ketoconazole. Avoid grapefruit products while taking Verzenio. Grapefruit may increase the amount of Verzenio in your blood How to take Use Verzenio exactly as your doctor tells you Take your doses of Verzenio at about the same time every day If you vomit or miss a dose take your next dose at your regular time. Do not take 2 doses of Verzenio at the same time to make up for the missed dose If you take too much Verzenio, call your doctor or go to the nearest hospital emergency room right away
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Ramiven (Abemaciclib 150 MG)

Ramiven (Abemaciclib 150 MG)
  • Ramiven (Abemaciclib 150 MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size14 Tablets
BrandRAMIVEN
CompositionAbemaciclib
ManufacturerEli Lilly and Company
TreatmentBreast Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

Ramiven (Abemaciclib 150 Mg) is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. ince September 2017 Abemaciclib is approved in the US for "adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones. Ramiven may cause serious side effects, including: Diarrhea is common with Ramiven, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Ramiven treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea. At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids. Low white blood cell counts (neutropenia) are common with Ramiven and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills. Ramiven may cause severe or life-threatening inflammation (swelling) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain Ramiven can cause liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems: Feeling very tired Loss of appetite Pain on the upper right side of your stomach area (abdomen) Bleeding or bruising more easily than normal Ramiven may cause blood clots in your veins or lungs. These may be serious and have led to death. Tell your doctor if you have the following signs and symptoms of a blood clot: Pain or swelling in your arms or legs Fast breathing Shortness of breath Fast heart rate Chest pain Ramiven can harm your unborn baby. Use effective birth control during treatment and for at least 3 weeks after the last dose of Ramiven and do not breastfeed during treatment with Ramiven and for at least 3 weeks after your last dose. Ramiven may affect the ability of males to father a child.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Zykadia (Ceritinib 150mg)

Zykadia (Ceritinib 150mg)
  • Zykadia (Ceritinib 150mg)
Get Best Quote
Approx. Price: Rs 10 / BottleGet Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Strength150mg
Packaging Size70 Capsule
BrandZYKADIA
CompositionCeritinib
ManufacturerNovartis Pharmaceuticals Corporation
TreatmentLung Cancer
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

ZYKADIA (Cerinib 150mg) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that: Is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body It is not known if ZYKADIA is safe and effective in children. IMPORTANT SAFETY INFORMATION ABOUT ZYKADIA What is the most important information I should know about ZYKADIA? ZYKADIA may cause serious side effects, such as: Stomach and intestinal (gastrointestinal) problems ZYKADIA may cause stomach and intestinal problems, including diarrhea, nausea, vomiting, and stomach-area pain. Follow your health care provider’s instructions about taking medicines to help with these symptoms. Call your health care provider for advice if your symptoms are severe or cannot be tolerated Liver problems ZYKADIA may cause liver injury. Your health care provider should perform blood tests at least every month to check your liver during treatment with ZYKADIA. Tell your health care provider right away if you experience any of the following symptoms: You feel tired Your skin or the whites of your eyes turn yellow You have a decreased appetite Your urine turns dark or brown (tea color) You have itchy skin You have nausea or vomiting You have pain on the right side of your stomach area You bleed or bruise more easily than normal Lung problems (pneumonitis) ZYKADIA may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your health care provider right away if you have any new or worsening symptoms, including: Trouble breathing or shortness of breath Cough, with or without mucus Fever Chest pain Heart problems ZYKADIA may cause very slow, very fast, or abnormal heartbeats. Your health care provider may check your heart during treatment with ZYKADIA. Tell your health care provider right away if you feel new chest pain or discomfort, dizziness or lightheadedness, faint, or have abnormal heartbeats. Tell your health care provider if you start to take or have any changes in heart or blood pressure medicines High blood sugar (hyperglycemia) People who have diabetes or glucose intolerance or those who take a corticosteroid medicine have an increased risk of high blood sugar with ZYKADIA. Your health care provider will check your blood sugar level before starting ZYKADIA and as needed during treatment with ZYKADIA. Call your health care provider right away if you have any symptoms of high blood sugar, including: Increased thirst Urinating often Increased hunger Blurred vision Headaches Tiredness Trouble thinking or concentrating Your breath smells like fruit Inflammation of the pancreas (pancreatitis) ZYKADIA can cause pancreatitis that has led to death. You may develop increased pancreatic enzyme blood levels, which may be a sign of pancreatitis. Signs and symptoms of pancreatitis include upper abdominal pain that may spread to the back and get worse with eating. Your health care provider should perform blood tests to check your pancreatic enzyme blood levels before you start ZYKADIA and as needed during your treatment Before you take ZYKADIA, tell your health care provider about all of your medical conditions, including if you: have liver problems have diabetes or high blood sugar have heart problems, including a condition called long QT syndrome have or have had pancreatitis are pregnant or plan to become pregnant. ZYKADIA can harm your unborn baby. Women who are able to become pregnant should use an effective method of birth control during treatment with ZYKADIA and for 6 months after stopping ZYKADIA. Talk to your health care provider about birth control methods that may be right for you. Tell your health care provider right away if you become pregnant or think that you may be pregnant.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Ruxolitinib (5mg ,10mg, 20mg)

Ruxolitinib (5mg ,10mg, 20mg)
  • Ruxolitinib (5mg ,10mg, 20mg)
  • Ruxolitinib (5mg ,10mg, 20mg)
  • Ruxolitinib (5mg ,10mg, 20mg)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size56 Tablets
CompositionRuxolitinib
TreatmentChronic Idiopathic Myelofibrosis
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years

Jakavi ( Ruxolitinib 5mg 10mg 20mg) Tablet is used in the treatment of chronic idiopathic myelofibrosis and Polycythemia vera.
Jakavi 5mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Headache, dizziness, low platelet count are some common side effects of this medicine. This medicine may reduce the number of blood cells (decrease red blood) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, kidney and lipid levels.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF JAKAVI TABLETPolycythemia veraChronic idiopathic myelofibrosisBENEFITS OF JAKAVI TABLETIn Polycythemia veraPolycythemia vera is a type of blood cancer that causes excessive production of red blood cells. This may lead to blood clot formation and lead to other serious health issues. Jakavi 5mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.Show MoreSIDE EFFECTS OF JAKAVI TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of JakaviHeadacheDizzinessLow blood plateletsAnemia (low number of red blood cells)HOW TO USE JAKAVI TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jakavi 5mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW JAKAVI TABLET WORKSJakavi 5mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEwarningsAlcoholSAFEConsuming alcohol with Jakavi 5mg Tablet does not cause any harmful side effects.warningsPregnancyCONSULT YOUR DOCTORJakavi 5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTORJakavi 5mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingUNSAFEJakavi 5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.warningsKidneyCAUTIONJakavi 5mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor.Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Tagrisso (Osimertinib 40MG)

Tagrisso (Osimertinib 40MG)
  • Tagrisso (Osimertinib 40MG)
  • Tagrisso (Osimertinib 40MG)
  • Tagrisso (Osimertinib 40MG)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Strength40mg
Packaging Size30 Tablets
BrandTagrisso
CompositionOsimertinib
ManufacturerAstra Zeneca
TreatmentLung Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years
Packaging TypeStrips
Storage25 DegreeC (77 DegreeF)

Tagrisso (Osimertinib 40mg) Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.
Tagrisso 40mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF TAGRISSO TABLETNon-small cell lung cancerBENEFITS OF TAGRISSO TABLETIn Non-small cell lung cancerNon-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Tagrisso 40mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.SIDE EFFECTS OF TAGRISSO TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of TagrissoDiarrheaLoss of appetiteRashStomatitis (Inflammation of the mouth)HOW TO USE TAGRISSO TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tagrisso 40mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW TAGRISSO TABLET WORKSTagrisso 40mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEwarningsAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Tagrisso 40mg Tablet. Please consult your doctor.warningsPregnancyCONSULT YOUR DOCTORTagrisso 40mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTORTagrisso 40mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingSAFETagrisso 40mg Tablet does not usually affect your ability to drive.warningsKidneySAFE IF PRESCRIBEDTagrisso 40mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Tagrisso 40mg Tablet is recommended.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Olaparib 150MG

Olaparib 150MG
  • Olaparib 150MG
  • Olaparib 150MG
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

BrandNA
Drug NameOlaparib
Dose/Strength150 Mg
Usage/ApplicationHospital
Grade StandardNA
Packaging TypeBottle
Packaging Size120 Tablet

Olaparib 150mg is a prescription medicine used to treat adults who have:
advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Olaparib  is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youadvanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. Olaparib  is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. Olaparib  is used after the cancer has responded to treatment with platinum-based chemotherapyadvanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that Olaparib  is right for youa certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youmetastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene. Olaparib  is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure Olaparib  is right for youprostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). Olaparib  is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure Olaparib  is right for youIt is not known if Olaparib  is safe and effective in children.IMPORTANT SAFETY INFORMATION Olaparib  may cause serious side effects, including:Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with Olaparib . MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Olaparib .
Symptoms of low blood cell counts are common during treatment with Olaparib , but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:before treatment with Olaparib every month during treatment with Olaparib 150mgweekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Olaparib  until your blood cell counts improve.






Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Osimertinib 40mg

Osimertinib 40mg
  • Osimertinib 40mg
  • Osimertinib 40mg
  • Osimertinib 40mg
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Strength40 mg
Packaging Size30 Tablets
CompositionOsimertinib
TreatmentLung Cancer
Prescription/Non prescriptionPrescription
FormTablet
Deals inThird Party Manufacturing
Shelf life2 Years
Medicine TypeAllopathic
Packaging TypeStrips
Storage25 DegreeC (77 DegreeF)

Osimertinib 40mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.
Osimertinib 40mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF TAGRISSO TABLETNon-small cell lung cancerBENEFITS OF TAGRISSO TABLETIn Non-small cell lung cancerNon-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Osimertinib 40mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.SIDE EFFECTS OF TAGRISSO TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of TagrissoDiarrheaLoss of appetiteRashStomatitis (Inflammation of the mouth)HOW TO USE TAGRISSO TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Osimertinib 40mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW TAGRISSO TABLET WORKSOsimertinib 40mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEwarningsAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Osimertinib 40mg Tablet. Please consult your doctor.warningsPregnancyCONSULT YOUR DOCTOROsimertinib 40mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTOROsimertinib 40mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingSAFEOsimertinib 40mg Tablet does not usually affect your ability to drive.warningsKidneySAFE IF PRESCRIBEDOsimertinib 40mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Osimertinib 40mg Tablet is recommended.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Sutent

Sutent
  • Sutent
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Minimum Order Quantity1 Box
Packaging Size7 Capsule
BrandSutent
CompositionSunitinib
ManufacturerPfizer
TreatmentKidney Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormCapsules
Shelf life2 Years
Country of OriginMade in India

SUTENT (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery. †SUTENT is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC). ‡SUTENT is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation. §SUTENT is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery. It is not known if SUTENT is safe and effective in children. IMPORTANT SAFETY INFORMATION SUTENT can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with SUTENT: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with SUTENT. Your healthcare provider may tell you to temporarily or permanently stop taking SUTENT if you develop liver problems. SUTENT may cause serious side effects, including: Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with SUTENT if you have signs and symptoms of heart failure. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with SUTENT. Tell your healthcare provider immediately if: you feel faint or lightheaded, or you pass out you feel dizzy you feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with SUTENT and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with SUTENT until your high blood pressure is controlled.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Jaknat (Tofacitinib 5 MG)

Jaknat (Tofacitinib 5 MG)
  • Jaknat (Tofacitinib 5 MG)
  • Jaknat (Tofacitinib 5 MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength / Dose5 mg
BrandJaknat
Packaging Size60 Tablets in a box (10 Tablets in a strip)
Packaging TypeStrip
CompositionTofacitinib
TreatmentRheumatoid Arthritis
Tablets in a Strip10
Prescription/Non prescriptionPrescription
ManufacturerNatco
Also givesThird Party Manufacturing
Shelf life2 Years

Jaknat (Tofacitinib 5 mg) can lower the ability of your immune system to fight infections. Do not start taking Jaknat  if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Jaknat . These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Jaknat .
Before and after starting Jaknat , tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Jaknat /Jaknat  XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Jaknat  5 mg twice daily or Jaknat  XR 11 mg one time each day.
Cancer. Jaknat  may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Jaknat  (10 mg twice daily) or Jaknat  XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Jaknat  with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Jaknat /Jaknat  XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Jaknat  and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Jaknat  can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Jaknat  and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Erivedge (Vismodegib 150MG)

Erivedge (Vismodegib 150MG)
  • Erivedge (Vismodegib 150MG)
  • Erivedge (Vismodegib 150MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

BrandErivedge
Dose Strength150mg
CategorySkin Cancer
CompositionVismodegib
Generic NameVismodegib
TypeAllopathic
Dosage FormOral
Packaging TypeBottle

Erivedge (Vismodegib 150mg) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. Important Safety Information What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. What should I tell my healthcare provider before taking Erivedge? If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose What are the possible side effects of Erivedge? Serious skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death. Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Orgovyx (Relugolix 120 Mg)

Orgovyx (Relugolix 120 Mg)
  • Orgovyx (Relugolix 120 Mg)
  • Orgovyx (Relugolix 120 Mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
Strength120 Mg
Pack Size30 Tablets
Storage30 DegreeC (86 DegreeF)
TreatmentProstate Cancer
Shelf life2 Years
TypeAllopathic

ORGOVYX (Relugolix 120 Mg) is a prescription medicine used for the treatment of advanced prostate cancer. It is the only androgen deprivation therapy (ADT) medicine that is not an injection. IMPORTANT SAFETY INFORMATION What should I tell my healthcare provider before taking ORGOVYX? Tell your healthcare provider about all of your medical conditions, including if you: Have any heart problems, including a condition called long QT syndrome. Are pregnant or plan to become pregnant. ORGOVYX can harm your unborn baby and cause loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ORGOVYX and for 2 weeks after the last dose of ORGOVYX. Are breastfeeding or plan to breastfeed. It is not known if ORGOVYX passes into your breast milk. Tell your healthcare provider about all the medicines or treatments you receive, including: prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking ORGOVYX with certain other medicines can affect how ORGOVYX works or may cause side effects. You should not start or stop any medicine before you talk with your healthcare provider who prescribed ORGOVYX. What are the possible side effects of ORGOVYX? Serious side effects of ORGOVYX include: Changes in the electrical activity of your heart (QT prolongation). Your healthcare provider may check your body salts (electrolytes) and the electrical activity of your heart during treatment with ORGOVYX. Tell your healthcare provider right away if you get any signs or symptoms of QT prolongation, including: dizziness fainting feeling that your heart is pounding or racing (palpitations) chest pain Most common side effects of ORGOVYX include: hot flushes increased blood sugar levels increased blood fat (triglyceride) levels muscle and joint pain decreased blood hemoglobin levels increased liver enzymes tiredness constipation diarrhea ORGOVYX may cause other side effects including weight gain, decreased sex drive, and erectile function problems. ORGOVYX may cause fertility problems in males, which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of ORGOVYX. Call your doctor for medical advice about side effects or if you have a side effect that bothers you or does not go away. You may report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. What is ORGOVYX? ORGOVYX is a prescription medicine used in adults for the treatment of advanced prostate cancer. It is not known if ORGOVYX is safe or effective in females or children.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Tafinlar (Dabrafenib 75mg)

Tafinlar (Dabrafenib 75mg)
  • Tafinlar (Dabrafenib 75mg)
  • Tafinlar (Dabrafenib 75mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
BrandNovartis
Dose Strength75mg
Grade StandardNA
CategorySkin Cancer
CompositionDabrafenib
Generic NameDabrafenib
TypeAllopathic
Dosage FormOral
Packaging TypeBottle

TAFINLAR (dabrafenib 75mg) Capsules Dabrafenib mesylate is a kinase inhibitor. TAFINLAR (dabrafenib) capsules for oral use are supplied as 50 mg and 75 mg capsules for oral administration. Each 50 mg capsule contains 59.25 mg dabrafenib mesylate equivalent to 50 mg of dabrafenib free base. Each 75 mg capsule contains 88.88 mg dabrafenib mesylate equivalent to 75 mg of dabrafenib free base. The inactive ingredients of TAFINLAR are colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Capsule shells contain hypromellose, red iron oxide (E172), and titanium dioxide. INDICATIONS Braf V600E Mutation-Positive Unresectable Or Metastatic Melanoma TAFINLAR is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test). Braf V600E Or V600K Mutation-Positive Unresectable Or Metastatic Melanoma TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION]. Adjuvant Treatment Of BRAF V600E Or V600K Mutation-Positive Melanoma TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection [see DOSAGE AND ADMINISTRATION]. DOSAGE AND ADMINISTRATION Patient Selection Melanoma Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR as a single agent [see WARNINGS AND PRECAUTIONS and Clinical Studies]. Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see WARNINGS AND PRECAUTIONS, Clinical Studies]. Information on FDA-approved tests for the detection of BRAF V600 mutations in melanoma is available at:  /CompanionDiagnostics. NSCLC Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see Clinical Studies]. Information on FDA-approved tests for the detection of BRAF V600E mutations in NSCLC is available at:  /CompanionDiagnostics. ATC Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see Clinical Studies]. An FDA-approved test for the detection of BRAF V600E mutation in ATC is not currently available. Recommended Dosage For Unresectable Or Metastatic Melanoma The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, as a single agent or in combination with trametinib, until disease progression or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information. Recommended Dosage For The Adjuvant Treatment Of Melanoma The recommended dosage of TAFINLAR is 150 mg orally taken twice daily in combination with trametinib until disease recurrence or unacceptable toxicity for up to 1 year. Refer to the trametinib prescribing information for recommended trametinib dosing information. Recommended Dosage For NSCLC The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, in combination with trametinib until disease recurrence or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information. Recommended Dosage For ATC The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, in combination with trametinib until disease recurrence or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Ixazomib 3mg,4mg

Ixazomib 3mg,4mg
  • Ixazomib 3mg,4mg
  • Ixazomib 3mg,4mg
  • Ixazomib 3mg,4mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
Dose Strength3mg,4mg
Grade StandardNA
CategoryBlood Cancer
CompositionIxazomib
Generic NameIxazomib
TypeAllopathic
Dosage FormOral
Packaging TypeBox

Ixazomib 3mg,4mg is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID (lenalidomide) and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma.
It is not known if Ixazomib  is safe and effective in children.
What are the possible side effects of Ixazomib ?
Ixazomib  may cause serious side effects, including:
Low platelet counts (thrombocytopenia). Low platelet counts are common with Ixazomib , and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising.Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with Ixazomib , and can sometimes be severe. Call your healthcare provider if you get any of these symptoms and they do not go away during treatment with Ixazomib . Your healthcare provider may prescribe medicine to help treat your symptoms.Nerve problems. Nerve problems are common with Ixazomib  and may also be severe. Tell your healthcare provider if you get any new or worsening symptoms, including:tinglingnumbnesspaina burning feeling in your feet or handsweakness in your arms or legsSwelling. Swelling is common with Ixazomib  and can sometimes be severe. Tell your healthcare provider if you develop swelling in your arms, hands, legs, ankles, or feet, or if you gain weight from swelling.Skin reactions. Tell your healthcare provider if you get a new or worsening rash.Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs, and may lead to death. Get medical help right away if you get any of the following signs or symptoms during treatment with Ixazomib :feverbruisingnose bleedstirednessdecreased urinationLiver problems. Tell your healthcare provider if you get these signs of a liver problem:yellowing of your skin or the whites of your eyespain in your right upper stomach-areaOther common side effects have occurred. Tell your healthcare provider if you get new or worsening signs or symptoms of the following:
back painskin rash and pain (shingles) as a result of reactivation of the chicken pox virus (herpes zoster)lowered white blood cells called neutrophils (neutropenia) that may increase the risk of infectionvision conditions including blurred vision, dry eye and pink eye (conjunctivitis)These are not all the possible side effects of Ixazomib . Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
DESCRIPTIONIxazomib  (ixazomib) is an antineoplastic agent. Ixazomib citrate, a prodrug, rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib. The chemical name of ixazomib citrate is 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-and the structural formula is:
Ixazomib ® (ixazomib) Structural Formula IllustrationThe molecular formula for ixazomib citrate is C20H23BCl2N2O9 and its molecular weight is 517.12. Ixazomib citrate has one chiral center and is the R-stereoisomer. The solubility of ixazomib citrate in 0.1N HCl (pH 1.2) at 37°C is 0.61 mg/mL (reported as ixazomib). The solubility increases as the pH increases.
Ixazomib  (ixazomib) capsules for oral use contain 4, 3 or 2.3 mg of ixazomib equivalent to 5.7, 4.3 or 3.3 mg of ixazomib citrate, respectively. Inactive ingredients include microcrystalline cellulose, magnesium stearate, and talc. Capsule shells contain gelatin and titanium dioxide.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Jakura (Tofacitinib 5MG)

Jakura (Tofacitinib 5MG)
  • Jakura (Tofacitinib 5MG)
  • Jakura (Tofacitinib 5MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength / Dose5 mg
BrandJakura
ManufacturerHetero Healthcare
Packaging TypeBottle
TreatmentRheumatoid Arthritis
Packaging Size1 x 60 (60 Tablets)
Prescription TypePrescription
Tablets in a Bottle60
Also givesThird Party Manufacturing
Shelf life2 Years

Jakura (Tofacitinib 5mg)can lower the ability of your immune system to fight infections. Do not start taking Jakura if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Jakura . These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Jakura .
Before and after starting Jakura , tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Jakura /Jakura XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Jakura 5 mg twice daily or Jakura XR 11 mg one time each day.
Cancer. Jakura may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Jakura (10 mg twice daily) or Jakura XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Jakura with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Jakura /Jakura XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Jakura and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Jakura can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Jakura and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking Jakura . Your doctor should also check certain liver tests. 



Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Lynparza ( Olaparib 150 Mg)

Lynparza ( Olaparib 150 Mg)
  • Lynparza ( Olaparib 150 Mg)
  • Lynparza ( Olaparib 150 Mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Piece
BrandLynparza
Drug NameOlaparib
Dose/Strength150 Mg
Usage/ApplicationPersonal
Grade StandardNA
Packaging TypeBottle
Packaging Size120 Tablet
Country of OriginMade in India
TreatmentBreast Cancer

LYNPARZA (Olaparib 150mg) is a prescription medicine used to treat adults who have:
advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youadvanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. LYNPARZA is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapyadvanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youa certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youmetastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure LYNPARZA is right for youprostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). LYNPARZA is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure LYNPARZA is right for youIt is not known if LYNPARZA is safe and effective in children.IMPORTANT SAFETY INFORMATION LYNPARZA may cause serious side effects, including:Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:before treatment with LYNPARZAevery month during treatment with LYNPARZA (Olaparib 150mg)weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.
Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Tasigna (Nilotinib 150mg,200mg)

Tasigna (Nilotinib 150mg,200mg)
  • Tasigna (Nilotinib 150mg,200mg)
  • Tasigna (Nilotinib 150mg,200mg)
  • Tasigna (Nilotinib 150mg,200mg)
  • Tasigna (Nilotinib 150mg,200mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Piece
Packaging Size28 Capsule
BrandTasigna
Composition150mg,200mg
ManufacturerNovartis India Ltd
TreatmentChronic Myeloid Leukemia
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormCapsules
Shelf life2 Years
Storage15 Degree-30 Degree C (59 Degree-86 Degree F)
Strength150mg,200mg

TASIGNA (nilotinib 150mg,200mg) capsules is a prescription medicine used to treat: Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phaseAdults with Ph+ CML in chronic phase IMPORTANT SAFETY INFORMATION ABOUT TASIGNA (nilotinib) Capsules
QTc Prolongation and Sudden Death: TASIGNA can cause QTc prolongation, a possibly life-threatening heart problem. QTc prolongation causes an irregular heartbeat, which may lead to sudden death. Call your doctor right away if you feel lightheaded, faint, or have an irregular heartbeat while taking TASIGNA. These can be symptoms of QTc prolongation.
Your doctor should check your heart with a test called an electrocardiogram (ECG)Do not take TASIGNA if you have long QTc syndrome or low levels of potassium or magnesium in your bloodTASIGNA can interact with many medicines and supplements. This may increase your chances for serious and life-threatening side effects. Do not take any other medicine while taking TASIGNA unless your doctor tells you it is okay to do soFood and grapefruit products increase the amount of TASIGNA in your body. This may increase your chances for serious and life-threatening side effects. Take TASIGNA on an empty stomachAvoid eating food for at least 2 hours before the dose is taken, and avoid eating food for at least 1 hour after the dose is takenAvoid grapefruit, grapefruit juice, and any supplement containing grapefruit extract while taking TASIGNATASIGNA can cause serious side effects that can even lead to death. During treatment with TASIGNA your doctor will do tests to check for side effects. These tests will check your heart, blood cells (white blood cells, red blood cells, and platelets), electrolytes (potassium, magnesium), cholesterol, blood sugar, and pancreas and liver function. Your doctor may have you stop TASIGNA for some time or lower your dose if you have side effects. You should follow your doctor’s instructions. Serious side effects include:
Low Blood Counts: Low blood counts are common with TASIGNA but can also be severe. Your doctor will check your blood counts regularly during treatment with TASIGNA. Call your doctor right away if you have symptoms of low blood counts including:Fever, chills, or other signs of infectionUnexplained bleeding or bruisingShortness of breathUnexplained weakness
Decreased Blood Flow to the Legs, Heart, or Brain: People who have recently been diagnosed with Ph+ CML and take TASIGNA may develop decreased blood flow to the legs, heart, or brain. Get medical help right away if you suddenly develop any of the following symptoms:Chest pain or discomfortNumbness or weaknessProblems walking or speakingLeg pain or your leg feels coldChange in the skin color of your leg
Pancreas Inflammation (Pancreatitis): Call your doctor if you have symptoms including sudden stomach area pain with nausea and vomiting

Liver Problems: TASIGNA can increase your risk of liver problems. People who have had liver problems in the past may be at risk for getting liver problems with TASIGNA. Call your doctor, or get medical help right away if you develop any symptoms of liver problems including stomach area (abdominal) pain, yellow skin/eyes, and dark-colored urine

Tumor Lysis Syndrome (TLS): TLS is caused by a fast breakdown of cancer cells. Your doctor may do blood tests to check you for TLS. TLS can cause you to have kidney failure (with the need for dialysis treatment) and/or an abnormal heartbeat

Bleeding Problems: Serious bleeding problems and death have happened during treatment with TASIGNA. Call your doctor right away if you develop signs and symptoms of bleeding such as uncontrolled bleeding, changes in eyesight, unconsciousness, sudden headache, or sudden confusion about your surroundings.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Erlotinib 150mg

Erlotinib 150mg
  • Erlotinib 150mg
  • Erlotinib 150mg
  • Erlotinib 150mg
  • Erlotinib 150mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Piece
Packaging Size30 Tablets
CompositionErlotinib
TreatmentLung Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years
Country of OriginMade in India

Erlotinib 150mg a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Erlotinib hydrochloride has the molecular formula C22H23N3O4.HCl and a molecular weight of 429.90. The molecule has a pKa of 5.42 at 25°C. Erlotinib hydrochloride is very slightly soluble in water, slightly soluble in methanol and practically insoluble in acetonitrile, acetone, ethyl acetate and hexane.  Aqueous solubility of erlotinib hydrochloride is dependent on pH with increased solubility at a pH of less than 5 due to protonation of the secondary amine. Over the pH range of 1.4 to 9.6, maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2.  Erlotinib  tablets for oral administration are available in three dosage strengths containing erlotinib hydrochloride (27.3 mg, 109.3 mg and 163.9 mg) equivalent to 25 mg, 100 mg and 150 mg erlotinib and the following inactive ingredients: lactose monohydrate, hypromellose, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate and titanium dioxide. The tablets also contain trace amounts of color additives, including FD&C Yellow 6 (25 mg only) for product identification. INDICATIONS Non-Small Cell Lung Cancer (NSCLC) Erlotinib ® Is Indicated For The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see Clinical Studies]. Limitations Of Use Safety and efficacy of Erlotinib  have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies]. Erlotinib  is not recommended for use in combination with platinum-based chemotherapy [see Clinical Studies]. DOSAGE AND ADMINISTRATION Selection of Patients with Metastatic NSCLC Select patients for the treatment of metastatic NSCLC with Erlotinib  based on the presence of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations in tumor or plasma specimens [See Clinical Studies]. If these mutations are not detected in a plasma specimen, test tumor tissue if available. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at:  .  Recommended Dose - NSCLC The recommended daily dose of Erlotinib  for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Revolade (Eltrombopag 25mg,50mg)

Revolade (Eltrombopag 25mg,50mg)
  • Revolade (Eltrombopag 25mg,50mg)
  • Revolade (Eltrombopag 25mg,50mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Piece
Packaging Size28 Tablets
BrandRevolade
CompositionEltrombopag
ManufacturerGlaxo SmithKline Pharmaceuticals Ltd
TreatmentAplastic anemia
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years
StorageThis medicine does not require any special storage conditions.
Strength25mg,50mg

Revolade (Eltrombopag 25mg,50mg) Tablet is used to treat low platelet count due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. It is also used to treat severe aplastic anemia. Revolade 50mg Tablet is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. The function of platelets is to help reduce bleeding. Take it in the exact dose and duration as advised by the doctor. You may take it on an empty stomach. This medicine is to be swallowed as a whole. Do not chew, crush or break it. Inform your doctor if you have any known allergies to this medication. The common side effects include nausea, vomiting, diarrhea, upper respiratory tract infection, and urinary tract infection. Let your doctor know if any of these side effects bother you. They may be able able to suggest ways to reduce or treat the symptoms. Before you take this medicine, inform your doctor if you have any preexisting medical conditions. Let your doctor also know about all the other medicines you are taking. Dose adjustments may be required in patients with liver diseases, inform your doctor. USES OF REVOLADE TABLET Low platelet count due to ITP or HCV infection Treatment of Severe Aplastic Anemia BENEFITS OF REVOLADE TABLET In Low platelet count due to ITP or HCV infection Revolade 50mg Tablet is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic idiopathic thrombocytopenic purpura (ITP, an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood). It is used in patients who have not benefited or cannot be treated with other treatments, including medications or surgery to remove the spleen. Revolade 50mg Tablet is also used to increase the number of platelets in people who have hepatitis C (a viral infection that may damage the liver). It is usually given along with other medicines. Show More SIDE EFFECTS OF REVOLADE TABLET Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Revolade Nausea Diarrhea Upper respiratory tract infection Vomiting Increased liver enzymes Muscle pain Urinary tract infection HOW TO USE REVOLADE TABLET Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Revolade 50mg Tablet is to be taken empty stomach. HOW REVOLADE TABLET WORKS Revolade 50mg Tablet is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. Platelets help to reduce or prevent bleeding. SAFETY ADVICE warnings Alcohol CONSULT YOUR DOCTOR It is not known whether it is safe to consume alcohol with Revolade 50mg Tablet. Please consult your doctor. warnings Pregnancy CONSULT YOUR DOCTOR Revolade 50mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor. warnings Breastfeeding CONSULT YOUR DOCTOR Revolade 50mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. warnings Driving UNSAFE Revolade 50mg Tablet may cause side effects which could affect your ability to drive.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Xeljanz (Tofacitinib 5 mg)

Xeljanz (Tofacitinib 5 mg)
  • Xeljanz (Tofacitinib 5 mg)
  • Xeljanz (Tofacitinib 5 mg)
  • Xeljanz (Tofacitinib 5 mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength / Dose5 mg
BrandXeljanz
Packaging Size60 Tablets
CompositionTofacitinib
Packaging TypeBottle
TreatmentRheumatoid Arthritis
Prescription/Non prescriptionPrescription
ManufacturerPfizer
Tablets in a Bottle60
Also givesThird Party Manufacturing
Shelf life2 Years

XELJANZ (Tofacitinib 5mg) can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ.
Before and after starting XELJANZ, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of XELJANZ/XELJANZ XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is XELJANZ 5 mg twice daily or XELJANZ XR 11 mg one time each day.
Cancer. XELJANZ may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of XELJANZ/XELJANZ XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Pomide (Pomalidomide 1mg,2mg,4mg)

Pomide (Pomalidomide 1mg,2mg,4mg)
  • Pomide (Pomalidomide 1mg,2mg,4mg)
  • Pomide (Pomalidomide 1mg,2mg,4mg)
  • Pomide (Pomalidomide 1mg,2mg,4mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
BrandPomide
TreatmentBlood Cancer
Country of OriginMade in India
Delivery TimeImmediate
TypeAllopathic
Dosage FormCapsule
Storage20 DegreeC -25 DegreeC (68 DegreeF -77 DegreeF)
DosageTake Pomide Capsule only as per the dose and duration suggested by your doctor.
Sub CategoryAnti Cancer
Pack Size21 Capsule

Pomide (Pomalidomide 1mg,2mg,4mg) is a prescription medicine used to treat adults with:
Multiple myeloma. Pomide  is taken along with the medicine dexamethasone, in people who:have received at least 2 prior medicines to treat multiple myeloma, including a type of medicine known as a proteasome inhibitor and lenalidomide, andtheir disease has become worse during treatment or within 60 days of finishing the last treatmentAIDS-related Kaposi sarcoma (KS). Pomide  is taken when highly active antiretroviral therapy (HAART) has not worked well enough or stopped working (failed)KS who do not have HIV infection (HIV negative).It is not known if Pomide  is safe and effective in children.
Who should not take Pomide ?
Do not take Pomide  if you:
are pregnant, plan to become pregnant, or become pregnant during treatment with Pomide . See “What is the most important information I should know about Pomide ?”are allergic to pomalidomide or any of the ingredients in Pomide . See the end of this Medication Guide for a complete list of ingredients in Pomide .What are the possible side effects of Pomide ?
Pomide  can cause serious side effects, including:
Low white blood cells (neutropenia), low platelets (thrombocytopenia), and low red blood cells (anemia) arecommon with Pomide , but can also be serious. You may need a blood transfusion or certain medicines if your blood counts drop too low. Your blood counts should be checked weekly for the first 8 weeks of treatment and monthly after that.Severe liver problems, including liver failure and death. Your healthcare provider should do blood tests to check your liver function during your treatment with Pomide . Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:Yellowing of your skin or the white part of your eyes (jaundice)Dark or brown (tea-colored) urinePain on the upper right side of your stomach area (abdomen)Bleeding or bruising more easily than normalFeeling very tiredSevere allergic reactions and severe skin reactions can happen with Pomide  and may cause death.Call your healthcare provider if you develop any of the following signs or symptoms during treatment with Pomide :
a red, itchy, skin rashpeeling of your skin or blisterssevere itchingfeverGet emergency medical help right away if you develop any of the following signs or symptoms during treatment with Pomide :
swelling of your lips, mouth, tongue, or throattrouble breathing or swallowingraised red areas on your skin (hives)a very fast heartbeatyou feel dizzy or faintDizziness and confusion. See “What should I avoid while taking Pomide ?Nerve damage. Stop taking Pomide  and call your healthcare provider if you develop symptoms of nerve damage including: numbness, tingling, pain, burning sensation in your hands, legs, or feet.Risk of new cancers (malignancies). New cancers, including certain blood cancers (acute myelogenous leukemia or AML) have been seen in people who received Pomide . Talk with your healthcare provider about your risk of developing new cancers if you take Pomide .Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.Your healthcare provider may tell you to stop taking Pomide  if you develop certain serious side effects during treatment.
The most common side effects of Pomide  in people with Multiple Myeloma include:
tiredness and weaknessconstipationnauseadiarrheashortness of breathupper respiratory tract infectionback painfever.
Request
Callback


Additional Information:

  • Item Code: NA1
  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Selpercatinib 80 Mg

Selpercatinib 80 Mg
  • Selpercatinib 80 Mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose Strength80mg
Grade StandardNA
CategoryLung Cancer
CompositionSelpercatinib
Generic NameSelpercatinib
TypeAllopathic
Dosage FormOral
Packaging TypeBottle

Selpercatinib 80mg is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC) that has spread, adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy), and adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Selpercatinibis right for you. It is not known if Selpercatinibis safe and effective in children younger than 12 years of age.
Selpercatinibwas approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long the response lasted. Studies are ongoing to confirm the benefit of Selpercatinibfor this use.
Selpercatinibmay affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.Important Facts About RETEVMO® (reh-TEHV-moh). It is also known as selpercatinib.
Selpercatinibis a prescription medicine that is used to treat certain cancers caused by an abnormal gene, called RET, in:
adults with non-small cell lung cancer (NSCLC) that has spread.adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who need a medicine that can be taken by mouth or injection.adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread, who need a medicine that can be taken by mouth or injection, and who have received radioactive iodine and it did not work or is no longer working.Your doctor will perform a test to make sure that Selpercatinibis right for you.
It is not known if Selpercatinibis safe and effective in children younger than 12 years of age.
Warnings
Selpercatinibmay cause serious side effects, including:
Liver problems: Liver problems (higher levels of liver enzymes) are common with Selpercatiniband may sometimes be serious. Your doctor will do blood tests before and during treatment with Selpercatinibto check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems during treatment:
yellowing of your skin or the white part of your eyes (jaundice)dark, “tea-colored” urinesleepinessbleeding or bruisingloss of appetitenausea or vomitingpain on the upper right side of your stomach areaIf you develop liver problems while taking RETEVMO, your doctor may lower your dose, stop treatment for a while, or stop treatment permanently.
High blood pressure (hypertension): High blood pressure is common with Selpercatinib  It may sometimes be serious. You should check your blood pressure regularly during treatment with Selpercatinib  Tell your doctor if you get any of the following symptoms during treatment:
confusionheadachesshortness of breathdizzinesschest painHeart rhythm changes (QT prolongation) can happen. These may be serious. Selpercatinibmay cause very slow, very fast, or irregular heartbeats. Tell your doctor right away if you get any of the following symptoms during treatment:
loss of consciousnessfaintingdizzinessa change in the way your heart beats (heart palpitations)Bleeding problems: Selpercatinibcan cause bleeding, which can be serious and may lead to death. 
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Cotellic (Cobimetinib 20mg)

Cotellic (Cobimetinib 20mg)
  • Cotellic (Cobimetinib 20mg)
  • Cotellic (Cobimetinib 20mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
CompositionCobimetinib
FormTablets
Packaging Size63 Tablets
Brand NameCOTELLIC
DosageTake COTELLIC Tablet only as per the dose and duration suggested by your doctor.
Packaging TypeBottle
Deals inThird Party Manufacturing
Type Of MedicinesAllopathic
TreatmentLung Cancer

COTELLIC (Cobimetinib 20mg) is a prescription medicine that is used with the medicine ZELBORAF, to treat a type of skin cancer called melanoma: that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene Your healthcare provider will perform a test to make sure that COTELLIC is right for you. It is not known if COTELLIC is safe and effective in children under 18 years of age. Before you take COTELLIC and ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you: have skin problems or history of skin problems, other than melanoma have bleeding problems, any medical conditions and/or on any medications that increase your risk of bleeding have heart problems, including a condition called long QT syndrome have eye problems have liver or kidney problems have muscle problems have had or are planning to receive radiation therapy have been told that you have low blood levels of potassium, calcium, or magnesium are pregnant or plan to become pregnant. COTELLIC and ZELBORAF can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with COTELLIC and ZELBORAF, and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later). Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with COTELLIC and ZELBORAF. are breastfeeding or plan to breastfeed. It is not known if COTELLIC or ZELBORAF passes into your breast milk. Do not breastfeed during treatment with COTELLIC and ZELBORAF and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later). Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the blood levels of COTELLIC. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take COTELLIC and ZELBORAF in combination? Take COTELLIC and ZELBORAF exactly as your healthcare provider tells you. Do not change your dose or stop taking COTELLIC and ZELBORAF unless your healthcare provider tells you to. Take COTELLIC one time a day for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Take ZELBORAF every 12 hours for every day in the 28-day cycle (no rest period). Do not crush or chew ZELBORAF tablets. Take COTELLIC and ZELBORAF with or without food. If you vomit after taking your dose of COTELLIC or ZELBORAF, do not take an additional dose. Take your next dose as scheduled. If you miss a dose of COTELLIC, take your next dose as scheduled. If you miss a dose of ZELBORAF, take it as soon as you remember. If it is within 4 hours of your next scheduled dose, just take your next dose at your regular time. Do not make up for the missed dose. If you take too much ZELBORAF, call your healthcare provider or go the nearest hospital emergency room right away. What should I avoid during treatment with COTELLIC and ZELBORAF? Avoid sunlight during treatment with COTELLIC and ZELBORAF. COTELLIC and ZELBORAF can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn: When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs. Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher. What are the possible side effects of COTELLIC and ZELBORAF?
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Kisqali (Ribociclib 200mg)

Kisqali (Ribociclib 200mg)
  • Kisqali (Ribociclib 200mg)
  • Kisqali (Ribociclib 200mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
BrandKISQALI
Dose Strength200mg
Grade StandardNA
CategoryBreast Cancer
CompositionRibociclib
Generic NameRibociclib

KISQALI (Ribociclib 200mg) is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy The KISQALI® (ribociclib) FEMARA (letrozole) Co-Pack is indicated as initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. IMPORTANT SAFETY INFORMATION Interstitial lung disease/pneumonitis. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with KISQALI and other CDK4/6 inhibitors. Across clinical trials in patients with advanced or metastatic breast cancer treated with KISQALI in combination with an aromatase inhibitor or fulvestrant (“KISQALI treatment groups”), 1.1% of KISQALI-treated patients had ILD/pneumonitis of any grade, 0.3% had grade 3 or 4, and 0.1% had a fatal outcome. Additional cases of ILD/pneumonitis have been observed in the postmarketing setting, with fatalities reported. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis, which may include hypoxia, cough, and dyspnea. In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt treatment with KISQALI immediately and evaluate the patient. Permanently discontinue treatment with KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis. Severe cutaneous adverse reactions. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients treated with KISQALI in the postmarketing setting. If signs or symptoms of SCARs occur, interrupt KISQALI until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If SCARs is confirmed, permanently discontinue KISQALI. Do not reintroduce KISQALI in patients who have experienced SCARs or other life-threatening cutaneous reactions during KISQALI treatment. QT interval prolongation. KISQALI and the KISQALI FEMARA Co-Pack have been shown to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction, or discontinuation. Across clinical trials in patients with advanced or metastatic breast cancer treated with KISQALI in combination with an aromatase inhibitor or fulvestrant (“KISQALI treatment groups”), 14 of 1054 patients (1%) had >500 ms postbaseline QTcF value, and 59 of 1054 (6%) had a >60 ms increase from baseline in QTcF intervals. These ECG changes were reversible with dose interruption and most occurred within the first 4 weeks of treatment. No cases of torsades de pointes were reported. In MONALEESA-2, on the KISQALI + letrozole treatment arm, there was 1 (0.3%) sudden death in a patient with grade 3 hypokalemia and grade 2 QT prolongation. No cases of sudden death were reported in MONALEESA-7 or MONALEESA-3.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Acalabrutinib 100mg

Acalabrutinib 100mg
  • Acalabrutinib 100mg
  • Acalabrutinib 100mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength100mg
Packaging Size12 Capsule
CompositionAcalabrutinib
TreatmentLymphoma
Prescription/Non prescriptionPrescription
FormCapsule
Deals inThird Party Manufacturing
Shelf life2 Years

Acalabrutinib 100mg is the generic name for the trade name drug Acalabrutinib . In some cases, health care professionals may use the trade name Acalabrutinib  when referring to the generic drug name acalabrutinib.
Drug Type: Acalabrutinib is a targeted therapy. Acalabrutinib inhibits the function of Bruton's tyrosine kinase (BTK) (for more detail, see "How Acalabrutinib Works" below).
What Acalabrutinib Is Used ForThe treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.The treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Acalabrutinib Is GivenAcalabrutinib is a 100 mg capsule, taken by mouth twice daily.Take acalabrutinib approximately 12 hours apart at the same time each day.Swallow acalabrutinib capsules whole with at least 8 ounces of water. Do not crush, open, chew or dissolve capsules.Take acalabrutinib with or without food.If you miss a dose by more than 3 hours, omit that dose and take the next dose at the regularly scheduled time; do not take extra doses to make up for a missed dose.The amount of acalabrutinib that you will receive depends on many factors including your general health or other health problems, other medications you may be taking, and severity or tolerance of side effects. Your doctor will determine your exact dosage and schedule.
Side EffectsImportant things to remember about the side effects of acalabrutinib:
Most people will not experience all of the acalabrutinib side effects listed.Acalabrutinib side effects are often predictable in terms of their onset, duration, and severity.Acalabrutinib side effects are almost always reversible and should improve after treatment is stoppedAcalabrutinib side effects may be quite manageable. There are many options to minimize or prevent the side effects of acalabrutinib.There is no relationship between the presence and/or severity of side effects and the effectiveness of the medication. Always report side effects to your healthcare provider.The following side effects are common (occurring in greater than 30%) for patients taking acalabrutinib:
HeadacheDiarrheaThese are less common side effects (occurring in 10-29%) for patients receiving acalabrutinib:
Low blood counts. Your white and red blood cells and platelets may temporarily decrease. This can put you at increased risk for infection, anemia and/or bleeding.FatigueBruisingMuscle painNauseaRashAbdominal painConstipationVomitingA rare, but potentially serious side effect of acalabrutinib is heart rhythm changes (arrhythmias), including atrial fibrillation and atrial flutter.
Not all side effects are listed above. Side effects that are very rare - occurring in less than about 10 percent of patients - are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms.
When to Contact Your Health Care ProviderContact your health care provider immediately, day or night, if you should experience any of the following symptoms:
Fever of 100.4º F (38º C) or higher, chillsShortness of breath, cough or trouble breathingAny bleeding that won't stopThe following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any of the following:

Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Tofacitinib 5 MG

Tofacitinib 5 MG
  • Tofacitinib 5 MG
  • Tofacitinib 5 MG
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength / Dose5 mg
BrandXeljanz
ManufacturerPfizer
Packaging TypeBottle
CompositionTofacitinib
Packaging Size1 x 60 (60 Tablets)
Prescription TypePrescription
Tablets in a Bottle60
FormTablet
Also givesThird Party Manufacturing
Shelf life2 Years

Tofacitinib 5 mg can lower the ability of your immune system to fight infections. Do not start taking Tofacitinib if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Tofacitinib. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Tofacitinib.
Before and after starting Tofacitinib, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Tofacitinib/Tofacitinib XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Tofacitinib 5 mg twice daily or Tofacitinib XR 11 mg one time each day.
Cancer. Tofacitinib may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Tofacitinib (10 mg twice daily) or Tofacitinib XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Tofacitinib with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Tofacitinib/Tofacitinib XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Tofacitinib and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Tofacitinib can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Tofacitinib and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.


Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Sutekast (Sunitinib 12.5mg,25mg,50mg)

Sutekast (Sunitinib 12.5mg,25mg,50mg)
  • Sutekast (Sunitinib 12.5mg,25mg,50mg)
  • Sutekast (Sunitinib 12.5mg,25mg,50mg)
  • Sutekast (Sunitinib 12.5mg,25mg,50mg)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size28 Capsule
BrandSutekast
CompositionSunitinib
ManufacturerAprazer
TreatmentKidney Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormCapsules
Shelf life2 Years
Country of OriginMade in India

Sutekast (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Sutekast is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Sutekast is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Sutekast is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Sutekast is safe and effective in children.IMPORTANT SAFETY INFORMATIONSutekast can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Sutekast:
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Sutekast. Your healthcare provider may tell you to temporarily or permanently stop taking Sutekast if you develop liver problems.
Sutekast may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Sutekast if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Sutekast. Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Sutekast and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Sutekast until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Sutekast, but Sutekast can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Sutekast, including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up bloodYour healthcare provider:
can tell you about other symptoms to watch formay do blood tests if needed and monitor you for bleedingSerious stomach and intestinal problems that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with Sutekast.





Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Rcnet (Sunitinib 12.5mg,25mg,50mg)

Rcnet (Sunitinib 12.5mg,25mg,50mg)
  • Rcnet (Sunitinib 12.5mg,25mg,50mg)
  • Rcnet (Sunitinib 12.5mg,25mg,50mg)
  • Rcnet (Sunitinib 12.5mg,25mg,50mg)
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size7 Capsule
BrandRcnet
CompositionSunitinib
ManufacturerBDR Pharmaceuticals Internationals Pvt. Ltd.
TreatmentKidney Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormCapsules
Shelf life2 Years

Rcnet (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Rcnet  is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Rcnet  is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Rcnet  is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Rcnet  is safe and effective in children.IMPORTANT SAFETY INFORMATIONRcnet  can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Rcnet :
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Rcnet . Your healthcare provider may tell you to temporarily or permanently stop taking Rcnet  if you develop liver problems.
Rcnet  may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Rcnet  if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Rcnet . Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Rcnet  and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Rcnet  until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Rcnet , but Rcnet  can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Rcnet , including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up bloodYour healthcare provider:
can tell you about other symptoms to watch formay do blood tests if needed and monitor you for bleedingSerious stomach and intestinal problems that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with Rcnet .



Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Sunitinib 12.5 MG, 25 MG, 50 MG

Sunitinib 12.5 MG, 25 MG, 50 MG
  • Sunitinib 12.5 MG, 25 MG, 50 MG
  • Sunitinib 12.5 MG, 25 MG, 50 MG
  • Sunitinib 12.5 MG, 25 MG, 50 MG
Get Best Quote
Approx. Price: Rs 10 / BoxGet Latest Price

Product Details:

Packaging Size7 Capsule
CompositionSunitinib
TreatmentKidney Cancer
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormCapsules
Shelf life2 Years
Country of OriginMade in India

Sunitinib 12.5mg,25mg,50mg is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Sunitinib   is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Sunitinib   is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Sunitinib   is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Sunitinib   is safe and effective in children.IMPORTANT SAFETY INFORMATIONSunitinib   can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Sunitinib  :
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Sunitinib  . Your healthcare provider may tell you to temporarily or permanently stop taking Sunitinib   if you develop liver problems.
Sunitinib   may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Sunitinib   if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Sunitinib  . Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Sunitinib   and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Sunitinib   until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Sunitinib  , but Sunitinib   can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Sunitinib  , including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up blood



Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Jakavi (Ruxolitinib 5mg ,10mg, 20mg)

Jakavi (Ruxolitinib 5mg ,10mg, 20mg)
  • Jakavi (Ruxolitinib 5mg ,10mg, 20mg)
  • Jakavi (Ruxolitinib 5mg ,10mg, 20mg)
  • Jakavi (Ruxolitinib 5mg ,10mg, 20mg)
  • Jakavi (Ruxolitinib 5mg ,10mg, 20mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Strip
Packaging Size56 Tablets
BrandJakavi
CompositionRuxolitinib
ManufacturerNovartis India Ltd
TreatmentChronic Idiopathic Myelofibrosis
Prescription/Non prescriptionPrescription
Deals inThird Party Manufacturing
FormTablet
Shelf life2 Years
Storage30 DegreeC
Strength5mg 10mg 20mg

Jakavi ( Ruxolitinib 5mg 10mg 20mg) Tablet is used in the treatment of chronic idiopathic myelofibrosis and Polycythemia vera.
Jakavi 5mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Headache, dizziness, low platelet count are some common side effects of this medicine. This medicine may reduce the number of blood cells (decrease red blood) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, kidney and lipid levels.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF JAKAVI TABLETPolycythemia veraChronic idiopathic myelofibrosisBENEFITS OF JAKAVI TABLETIn Polycythemia veraPolycythemia vera is a type of blood cancer that causes excessive production of red blood cells. This may lead to blood clot formation and lead to other serious health issues. Jakavi 5mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.Show MoreSIDE EFFECTS OF JAKAVI TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of JakaviHeadacheDizzinessLow blood plateletsAnemia (low number of red blood cells)HOW TO USE JAKAVI TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jakavi 5mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW JAKAVI TABLET WORKSJakavi 5mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEwarningsAlcoholSAFEConsuming alcohol with Jakavi 5mg Tablet does not cause any harmful side effects.warningsPregnancyCONSULT YOUR DOCTORJakavi 5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTORJakavi 5mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingUNSAFEJakavi 5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.warningsKidneyCAUTIONJakavi 5mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor.Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Opdivo (Nivolumab 40mg & 100mg)

Opdivo (Nivolumab 40mg & 100mg)
  • Opdivo (Nivolumab 40mg & 100mg)
  • Opdivo (Nivolumab 40mg & 100mg)
  • Opdivo (Nivolumab 40mg & 100mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Vial
CompositionNivolumab
Storage2 DegreeC to 8 DegreeC (36 DegreeF to 46 DegreeF)
TreatmentLung Cancer
Strength40mg & 100mg
Pack Size1Vial
DosageTake OPDIVO Vial only as per the dose and duration suggested by your doctor
Dosage FormInjection

OPDIVO (nivolumab 40mg 100mg) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene. OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene. OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use. For people with previously treated advanced non-small cell lung cancer OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working. For people with advanced melanoma OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use. For people with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery. For certain people with advanced kidney cancer (renal cell carcinoma) OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with kidney cancer in certain people when their cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use. For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat people with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib. For people with previously treated advanced kidney cancer (renal cell carcinoma) OPDIVO® (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications. For people with previously treated squamous cell carcinoma of the head and neck OPDIVO® (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working. For people with liver cancer (hepatocellular carcinoma) that have received treatment with sorafenib.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Nivolumab 40mg,100mg

Nivolumab 40mg,100mg
  • Nivolumab 40mg,100mg
  • Nivolumab 40mg,100mg
  • Nivolumab 40mg,100mg
Ask For Price
Product Price :Get Latest Price

Product Details:

CompositionNivolumab
Strength40mg & 100 mg
Storage2 DegreeC to 8 DegreeC (36 DegreeF to 46 DegreeF)
TreatmentLung Cancer
Shelf life2 Years
DosageTake Nivolumab Vial only as per the dose and duration suggested by your doctor
Delivery TimeImmediate

Nivolumab 40mg,100mg is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
Nivolumab is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For people with previously treated advanced non-small cell lung cancer
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
For people with advanced melanoma
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).Nivolumab  (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For people with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
For certain people with advanced kidney cancer (renal cell carcinoma)
Nivolumab  (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with kidney cancer in certain people when their cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
Nivolumab  (nivolumab) is a prescription medicine used in combination with cabozantinib to treat people with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
For people with previously treated advanced kidney cancer (renal cell carcinoma)
Nivolumab  (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
For people with previously treated squamous cell carcinoma of the head and neck
Nivolumab  (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.




Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Spexib (Ceritinib 150mg)

Spexib (Ceritinib 150mg)
  • Spexib (Ceritinib 150mg)
  • Spexib (Ceritinib 150mg)
  • Spexib (Ceritinib 150mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Packing size150 Capsule
TreatmentLung Cancer
TypeAllopathic
Storage25 DegreeC (77 DegreeF)
Minimum Order Quantity1 Box
DISCLAIMERTrademark shown are property of their respective owners and we do not lay any claim on them. Parall

Spexib (Ceritinib 150mg) Capsule is used in the treatment of non-small cell lung cancer. It shows its working by stopping or slowing down the growth of cancer cells.

Spexib Capsule should be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Fatigue, nausea, vomiting, and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include tiredness, itchy skin, yellowing of your skin, and chest pain or discomfort, changes in your heartbeat. Your doctor may perform some blood tests before and after the treatment to check for liver, or blood sugar level.

Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF SPEXIB CAPSULE
  • Non-small cell lung cancer
BENEFITS OF SPEXIB CAPSULEIn Non-small cell lung cancerNon-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Spexib Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.SIDE EFFECTS OF SPEXIB CAPSULEMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of Spexib
  • Diarrhea
  • Fatigue
  • Nausea
  • Vomiting
HOW TO USE SPEXIB CAPSULETake this medicine in the dose and duration as advised by your doctor. Spexib Capsule may be taken with or without food, but it is better to take it at a fixed time.HOW SPEXIB CAPSULE WORKSSpexib Capsule is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Spexib Capsule. Please consult your doctor.PregnancyCONSULT YOUR DOCTORSpexib Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.BreastfeedingCONSULT YOUR DOCTORInformation regarding the use of Spexib Capsule during breastfeeding is not available. Please consult your doctor.DrivingUNSAFESpexib Capsule may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.KidneySAFE IF PRESCRIBEDSpexib Capsule is safe to use in patients with kidney disease. No dose adjustment of Spexib Capsule is recommended.LiverSAFE IF PRESCRIBEDSpexib Capsule is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Spexib Capsule may not be needed in these patients. Please consult your doctor.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested
X

Explore More Product

View All Product


Reach Us
Rakshit Jain (Sales & Marketing Manager)
Bull Pharmachem
No. 64C, Dhan Sadan Co Operative Housing Society, 2nd Floor
Kalbadevi, Mumbai - 400002, Maharashtra, India


Call Us


Send E-mail